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ABSTRACT OF DISSERTATION

ANDROGEN INCREASES ANGIOTENSIN RECEPTOR TYPE 1A ON SMOOTH
MUSCLE CELLS TO PROMOTE ANGIOTENSIN II-INDUCED ABDOMINAL
AORTIC ANEURYSMS
The purpose of this study was to determine whether androgen promotes
AT1aR expression on smooth muscle to confer high prevalence of AngII-induced
AAAs in hyperlipidemic mice. In addition, we also investigate the role of
androgen in the progression of established AngII-induced AAAs.
First, we sought to examine the role of endogenous androgen in the
growth of established AngII-induced AAAs. By castrating male mice, we
demonstrated that removal of endogenous androgen significantly decreased the
progressive lumen dilation of established AngII-induced AAAs in male ApoE-/mice, but had no e ffect on external AAA diameters. These results suggest that
androgen contributes to the progression of established AAAs through distinct
mechanisms that differentially influence aortic lumen and wall diameters.
We also investigate whether androgen regulates aortic AT1aR expression
to promote AngII-induced AAA formation. Our data demonstrated that in male
and female mice, both endogenous and exogenous androgen stimulate AT1aR
level particularly in abdominal aortas. This androgen-dependent enhanced
expression of abdominal aortic AT1aR was correlated with increased AngIIinduced AAA formation in male and f emale mice. Smooth muscle AT1aR
deficiency significantly reduced luminal and external diameters of abdominal
aortas as well as the incidence of AngII-induced AAAs in adult female mice
administered exogenous androgen. Collectively, these results indicate that in
adult mice androgen stimulate smooth muscle AT1aR expression to promote
AngII-induced AAA formation.
To determine the role of androgen during development on AT1aR
expression on SMC and AngII-induced vascular pathologies, we exposed
neonatal female mice to one single dose of testosterone. Our data demonstrated
that neonatal testosterone administration dramatically increased AngII-induced
AAA, atherosclerosis and ascending aortic aneurysms in adult female mice. In

addition, smooth muscle AT1aR deficiency reduced effects of neonatal
testosterone to promote AAAs, but had no effect on the other two AngII-induced
vascular pathologies.
In summary, our findings demonstrated that androgen, both in adult life
and during development, stimulate smooth muscle AT1aR expression and
promote AngII-induced AAA in female hyperlipidemic mice.
KEYWORDS: Androgen, Angiotensin receptor, Abdominal aortic aneurysm,
Sexual dimorphism, Smooth muscle
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CHAPTER I. BACKGROUND

1.1

Abdominal Aortic Aneurysms in Humans

1.1.1 Overview
According to the Society for Vascular Surgery and the International
Society for Cardiovascular Surgery abdominal aortic aneurysms (AAAs) are
defined as a permanent dilation of the infrarenal aorta with a ratio of ≥1.5 fold
increase in normal abdominal aortic diameter (Johnston, Rutherford et al. 1991).
Most investigators also define an AAA as an infrarenal aortic diameter
exceeding 3.0 cm (McGregor, Pollock et al. 1975; Sakalihasan, Limet et al.
2005). The prevalence of unsuspected, asymptomatic AAA in men and women
over the age of 60 years are 4% to 8.5% and 0.5% to 1.5%, respectively
(Wilmink, Quick et al. 1999; Lawrence-Brown, Norman et al. 2001; Ashton,
Buxton et al. 2002; Cornuz, Sidoti Pinto et al. 2004; Palombo, Lucertini et al.
2010). AAAs tend to progressively expand over time with average growth rate
between 0.25 and 0.32 cm/year (Lederle, Wilson et al. 2002) . The risk of
aneurysmal rupture increases proportionally with AAA diameter, and becomes
especially high when the diameter exceeds 5.5 cm. Unfortunately, so far there
are no pharmacologic treatments with proven efficacy to prevent AAA expansion
and rupture. Currently the only effective way to prevent AAA rupture is open or
endovascular surgical repair. A threshold of 5.0 – 5.5 cm in AAA size is the
current recommendation for open or endovascular surgical repair of an AAA
(Powell and Brady 2004). Recent estimates of AAA prevalence are 1.1 million
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people in the US between the ages of 50 to 84 (Kent, Zwolak et al. 2010).
Ruptured AAA and complications after surgical treatment are responsible for at
least 15,000 deaths per year in the United States (Gillum 1995). This number is
considered as a likely understatement because about 5% of the 200,000 people
who die of sudden death each year may have died from AAA ruptures
(Schermerhorn 2009).
The histopathologic features of human AAAs are characterized by chronic
excessive transmural inflammatory (B-cells, T-cells and macrophage infiltration),
destructive degradation of the elastic media, apoptosis of medial smooth muscle
cells (SMCs) and significant medial neovascularization (Choke, Cockerill et al.
2005). However, the detailed mechanisms involved in biochemical and cellular
processes during the development of human AAAs remains largely unknown. It is
now well accepted that AAA initiation, progression and rupture are multifactorial
biological processes that involve distinct biochemical, cellular and proteolytic
influences and biomechanical factors on the vessel wall during different
developmental stage of AAA pathogenesis. It is well established that the
destruction of elastin and collagen largely contributes to the decrease in aortic
wall tensile strength followed by aneurysmal dilatation. In rodents, elastase
infusion into infrarenal aortas induces AAA formation (Halpern, Nackman et al.
1994). Increased proteolytic activity in the vessel wall has been demonstrated to
play a significant role in the pathogenesis of AAAs. Increased levels of matrix
metalloproteinases (MMPs), specially MMP-2 and MMP-9, were found in
aneurysmal tissues of both humans and experimental models (Freestone, Turner
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et al. 1995; Goodall, Porter et al. 2002) and the genetic deficiency of MMP 2 and
9 inhibit AAA formation in an experimental AAA model (Longo, Xiong et al. 2002).
As reviewed by Takagi et al, higher circulating MMP-9 concentrations are
associated with AAA in human (Takagi, Manabe et al. 2009). Furthermore,
plasma MMP-9 levels were elevated in patients with larger AAAs (Lindholt,
Vammen et al. 2000; Petersen, Gineitis et al. 2000). Increased MMP-9 level was
detected at the ruputure site of AAAs (Wilson, Anderton et al. 2006). Also a 4fold increase in pre-operative plasma MMP-9 levels was associated with
increased mortality >30 days post-rupture surgery, compared to >30 days post
surgery survivors (Wilson, Anderton et al. 2008). All these findings demonstrate
an important role of MMPs in the pathogenesis of human AAAs.

1.1.2 Clinical risk factors
Smoking, male gender, aging, and family history are considered as
primary and independent risk factors of human AAA (Pleumeekers, Hoes et al.
1995; Lederle, Johnson et al. 2000; Wanhainen, Bergqvist et al. 2005). Smoking
is a prominent risk factor that is strongly associated with AAAs development.
Approximately 90% of people with AAAs have smoked (Powell and Greenhalgh
2003; Isselbacher 2005). People who have smoked for more than 40 years are
much more likely to develop AAAs compared to non-smokers (Powell and
Greenhalgh 2003) A slow decline in risk was observed with each year after
cessation of smoking (Wilmink, Quick et al. 1999; Lederle, Johnson et al. 2001;
Kent, Zwolak et al. 2010). Age, hypertension, hyperlipidemia and atherosclerosis
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were also found to be moderate risk factors for developing AAAs (Wanhainen,
Bergqvist et al. 2005; Kent, Zwolak et al. 2010). Genetics also plays a role in the
development of AAAs. For example, people with a family history of AAAs have a
30% greater risk, and their aneurysms tend to develop at a younger age
compared to those with no family history of the disease (Frydman, Walker et al.
2003). Recently It has been reported that the relative risk of developing AAA for
first-degree relatives to persons with diagnosed AAA is approximately doubled
compared to persons with no family history (Larsson, Granath et al. 2009).
Genetic variations in several chromosome loci, including 19q13, 4q31and 9p21,
have been associated with AAA formation (Shibamura, Olson et al. 2004;
Kuivaniemi, Kyo et al. 2006; Helgadottir, Thorleifsson et al. 2008). Recently
obesity has been demonstrated to be associated with increased risk for AAA
formation in human and experimental AAA model (Golledge, Clancy et al. 2007;
Police, Thatcher et al. 2009). Interestingly, a negative association have been
observed between AAA and diabetes mellitus (Blanchard, Armenian et al. 2000).
Black and Asian race were also found to be associated with decreased risk of
AAA (Iribarren, Darbinian et al. 2007).

1.1.3 Gender
Gender is considered a major independent risk factor for AAA
development (Wanhainen, Bergqvist et al. 2005; Forsdahl, Singh et al. 2009). For
example, men are 10 times more likely to develop an AAA of 4 cm or greater
compared to age-matched women (Lederle, Johnson et al. 2001). Overall, men

4

exhibit greater incidence and severity of AAA compared to women. In recent
decades epidemiological studies have demonstrated increased AAA incidence
and rupture in western societies, especially in male gender (Best, Price et al.
2003; Acosta, Ogren et al. 2006). The well described risk of male gender has
influenced clinical care, as men aged 65 to 75 years with a history of smoking are
strongly recommended with regular ultrasound screening for AAA.
However, female gender has been associated with higher rupture risk of
small aneurysms (3 times more frequently and at a smaller diameter compared to
men), and decreased survival rate after surgical AAA repair (Noel, Gloviczki et al.
2001; Norman and Powell 2007; Grootenboer, van Sambeek et al. 2010).
Furthermore, recent studies reported a significantly increased growth rate of
AAAs in women compared to men (Solberg, Singh et al. 2005; Mofidi, Goldie et
al. 2007; Norman and Powell 2007).

1.2

Renin-angiotensin system

1.2.1 Current view
Ever since its first discovery in 1898, the renin-angiotensin system(RAS)
has emerged as a vital system to modulate many physiological and pathological
processes. Besides its classical effects on regulating blood pressure and
maintaining fluid volume homeostasis, the RAS also plays a pivotal role in renal
and cardiovascular pathologies. Angiotensin peptides are produced through
sequential enzymatic cleavage of the only known precursor, angiotensinogen as
illustrated in Figure 1.1. Angiotensinogen, a 58 kD glycoprotein consisting of 452
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amino acids, is mainly synthesized and secreted by hepatic cells into the
circulation (Devenyi, Dauda et al. 1968; Kageyama, Ohkubo et al. 1984).
However, angiotensinogen mRNA is also expressed in various tissues, including
adipose tissue (Cassis 2000).
Renin is an aspartyl protease that cleaves off 10 amino acids at the amino
terminus of angiotensinogen to yield the peptide angiotensin I. Secretion of renin
is activated primarily in response to decreases in blood pressure and sodium
content. Circulating renin and its precursor, prorenin, is synthesized and released
primarily from the juxtaglomerular cells located in the glomerular afferent
arterioles (Levens, Peach et al. 1981). In addition, renin has been localized to the
brain (Inagami, Celio et al. 1980); blood vessels (Mizuno, Gotoh et al. 1984),
ovaries (Lightman, Jones et al. 1988), testis (Pandey, Melner et al. 1984),
macrophages (Lu, Rateri et al. 2008), and adipose tissue (Cassis 2000).
Prorenin is more abundant in the circulation. In human blood plasma, prorenin
levels are about 10-fold higher than renin (Danser, Derkx et al. 1998). For a long
time prorenin had been considered to be a mere inactive precursor of renin until
the (pro)renin receptor, a 350 amino acid protein with a single transmembrane
domain, was identified and cloned in 2002 (Nguyen, Delarue et al. 2002). The
(pro)renin receptor has been shown to bind both renin and prorenin. In humans,
the prorenin receptor binds prorenin preferentially (Kd ~6-8 nM vs. >20 nM for
renin) (Nabi, Kageshima et al. 2006; Jan Danser, Batenburg et al. 2007; Danser,
Batenburg et al. 2008). Binding of prorenin to the (pro)renin receptor induces a
conformational change in the prorenin molecule, allowing it to display full
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enzymatic activity without undergoing proteolytic cleavage to renin (Batenburg,
Krop et al. 2007). Recently it has been demonstrated that renin and prorenin also
acted as agonists for the (pro) renin receptor and induce angiotensinindependent effects, such as triggering activation of the mitogenactivated protein
kinase (MAPK), extracellular signalregulated kinase (ERK) 1/2 signaling pathway
and upregulating transforming growth factor β1 (TGF-β1) gene expression
(Huang, Noble et al. 2007; Feldt, Batenburg et al. 2008).
Angiotensin I (AngI) is biologically inactive and is rapidly converted to
AngII through an enzymatic cleavage of the last 2 amino acids at the carboxy
terminus by the angiotensin-converting enzyme (ACE). Two forms of ACE are
produced from a single gene through alternate promoters (Ehlers and Riordan
1989). Somatic ACE is the 160 to 170 kDa protein formed primarily in endothelial
cells of the lung (Ryan, Ryan et al. 1975). It has also been found in kidney
(Wallace, Bailie et al. 1978), intestine (Bruneval, Hinglais et al. 1986), placenta
(Sim and Seng 1984) and adipose tissue (Karlsson, Lindell et al. 1998) as well as
vascular endothelium, epithelium and macrophages (Fuchs, Xiao et al. 2004)
Germinal ACE is a 100 to 110 kDa protein produced by germ cells in the
testis (Ehlers and Riordan 1989; Bernstein, Howard et al. 1992). Mice with ACE
deficiency exhibits reduced blood pressure, inability to concentrate urine,
reduced aldosterone production and serum potassium concentrations and
defects in renal structure and function (Kim, Krege et al. 1995; Esther, Howard et
al. 1996). ACE inhibitors are widely used to treat hypertension and congestive
heart failure. Besides Ang I, ACE acts on a number of natural substrates
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including bradykinin (Ryan, Ryan et al. 1975), cholecystokinin (Dubreuil,
Fulcrand et al. 1989) substance P (Couture and Regoli 1981) and luteinizing
hormone-releasing hormone (Skidgel and Erdos 1985).
Recently a homologue of ACE, known as angiotensin-converting enzyme
2 (ACE2), was identified. ACE2 is predominantly expressed in vascular
endothelial cells of the heart and kidney (Donoghue, Hsieh et al. 2000; Tipnis,
Hooper et al. 2000). ACE2 expression has also been detected in adipocytes,
testes, colon and lung (Hamming, Timens et al. 2004; Gupte, Boustany-Kari et al.
2008). Unlike ACE, ACE2 is a monocarboxypeptidase, cleaving a single
carboxyl-terminal residue from its substrates. Both Ang I and AngII can be
catabolized by ACE2 to generate Ang-(1-9), and Ang-(1-7), respectively
(Donoghue, Hsieh et al. 2000; Tipnis, Hooper et al. 2000). However, ACE2
exhibits a 400-fold higher catalytic efficiency to hydrolyze AngII as a substrate
compared to AngI (Vickers et al. 2002). Interestingly, Ang-(1-7) is a vasodilator
and exhibits vasoprotective effects. Ang-(1-7) mediates its effects via interaction
with Mas, a G protein coupled receptor. It has been demonstrated that Ang-(1-7)
induces vasodilation through endothelium-dependent nitric oxide involving
bradykinin receptors (Brosnihan et al. 1996). Ang-(1-7) has also been
demonstrated to have antiproliferative, antitrophic and apoptotic effects. Thus,
ACE2/Ang-(1-7) has been suggested as the counter balancing arm of the RAS.
As the most potent vasoconstrictor of the RAS, AngII plays a critical role in
regulating blood pressure and fluid electrolyte balance (Peach, Cline et al. 1966).
AngII has been demonstrated to increase blood pressure via eliciting
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vasoconstriction in vascular smooth muscle cells (Chiu, Roscoe et al. 1991) and
modulating vascular structure. In the vasculature, AngII exhibit mitogenic effects
and cause vascular smooth muscle cell growth (Touyz and Schiffrin 1997),
proliferation (Stouffer and Owens 1992) and hypertrophy (Chiu, Roscoe et al.
1991). In addition, AngII increases intravascular volume to further enhance total
peripheral resistance, therefore increasing blood pressure. AngII regulates water
and sodium reabsorption by stimulating the synthesis and release of aldosterone
from the adrenal cortex (Laragh, Ulick et al. 1960; Carpenter, Davis et al. 1961).
AngII also induces water retention and a dipsogenic response by increasing the
release of vasopressin from the pituitary (Epstein, Fitzsimons et al. 1969; Phillips,
Rolls et al. 1985). In the adrenal medulla, AngII stimulates catecholamine release
from the chromaffin cells (Peach, Cline et al. 1966). Moreover, Ang II also
increases blood pressure by facilitating peripheral noradrenergic
neurotransmission. AngII has been demonstrated to enhance vascular
vasopressor responses to norepinephrine (Reams et al. 1987), facilitate
norepinephrine release from sympathetic nerve terminals (Hughes et al. 1971)
and inhibit norepinephrine reuptake during sympathetic stimulation (Campbell,
Brooks et al. 1974). AngII can also act in the area postrema of the brain to
increase sympathetic drive to the periphery, and thus increase blood pressure
(Meldrum, Xue et al. 1984; Papouchado, Vatta et al. 1995).
AngII exerts its physiological and pathophysiological biological actions via
binding to specific receptors on the cell surface. AngII receptors belong to the
seven transmembrane class of G-protein-coupled receptors (GPCR), and are
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divided into two main distinct subtypes: angiotensin II type 1 (AT1) and 2 (AT2)
receptors (Lin and Goodfriend 1970). These two receptors were initially defined
based on their differential pharmacological and biochemical properties. The
majority of the well-known AngII effects, which includes vasoconstriction (Touyz
and Schiffrin 1997), cellular growth and differentiation (Huang, Richards et al.
1996), tubular reabsorption (Navar, Harrison-Bernard et al. 1999) and
aldosterone synthesis and secretion (Balla, Baukal et al. 1991) are mediated via
AT1R. The AT1R is ubiquitously expressed in many cells and tissues, such as
vascular smooth muscle cells, kidney, heart, adrenal gland, brain, lung, and
adipose tissues (Murphy, Alexander et al. 1991). The intracellular signaling
pathways involved in AT1R action are illustrated by Figure 1.2. AT1R triggers the
activation of classic G protein coupled intracellular signalling pathways, which
includes coupling to a GTP-binding protein, activation of a phospholipase C
resulting in inositol trisphosphate generation, and mobilization of intracellular
Ca2+ stores and diacylglycerol formation leading to protein kinase C activation
(Farese, Larson et al. 1984). In addition to the G protein mediated pathways,
AngII also act through AT1R to cross talk with several tyrosine kinases and
activate mitogen-activated protein kinases (MAPKs), including extracellular
signaling regulation kinase (ERK1/2), JNK and p38MAPK (Mehta and Griendling
2007). Unlike human, rodents have 2 isoforms of AT1R that share 95% amino
acid sequence similarity, AT1aR on chromosome 17 and AT1bR on chromosome
2 (Elton, Stephan et al. 1992; Sasamura, Hein et al. 1992). Studies have
demonstrated that mice with AT1aR deficiency, but not AT1bR deficiency, have
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decreased blood pressure and an attenuated response to AngII (Ito, Oliverio et
al. 1995; Chen, Li et al. 1997; Oliverio, Best et al. 2000), suggesting the AT1aR is
the major receptor subtype involved in blood pressure regulation in mice.
Recently, it has been demonstrated that AT1bR predominantly mediates
contraction in the isolated abdominal aorta and femoral artery (Zhou, Chen et al.
2003; Zhou, Dirksen et al. 2005; Swafford, Harrison-Bernard et al. 2007).
Moreover, AngII infusion induces a pressor response in AT1aR deficient mice,
which can be blocked by AT1R antagonists. These data suggest that AT1bR
receptors may play a role in blood pressure regulation in the absence of AT1aR
(Oliverio, Best et al. 1997).
In contrast to the AT1 receptor, the physiological significance of the AT2R
is less understood. AT2R seems to counterbalance some of the effects
mediated by AT1R as illustrated in Figure 1.3. It has been demonstrated that AT2
antagonize effects of the AT1 receptor by promoting vasorelaxation, growth
inhibition, and proapoptotic effects (Akishita, Yamada et al. 1999). AT2R deficient
mice exhibit a 10 mmHg increase in blood pressure (Gross, Obst et al. 2004) and
enhanced sensitivity to the pressor effects of AngII infusion (Hein, Barsh et al.
1995; Ichiki, Labosky et al. 1995). Unlike AT1R, whose expression level remain
relatively constant in adults, AT2R is mainly present during late embryonic
development and in the neonate of the mouse and rat, but levels rapidly decline
shortly after birth (Nakajima, Hutchinson et al. 1995; Shanmugam, Corvol et al.
1996; Horiuchi, Yamada et al. 1997). AT2R is believed to play a role in
physiological development, partially through its effects on vascular remodeling. In
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adults, AT2R expression is largely restricted to kidneys, adrenals, uterus, ovary,
heart and specialized nuclei in the brain. Interestingly, AT2R is upregulated in
many cardiovascular pathological conditions associated with inflammation or
tissue remodeling such as heart or renal failure (Ohkubo, Matsubara et al. 1997),
myocardial infarction (Nio, Matsubara et al. 1995), vascular injury, and wound
healing (Kimura, Sumners et al. 1992).
Angiotensin (2-8) (AngIII), another biologically active peptide of the RAS is
generated from Ang II by aminopepetidase A (Vaughan et al.1974; Kugler et
al.1982). AngIII has high affinity for AT1 and AT2 receptors and can induce
vasoconstriction, aldosterone release and sodium retention (Zini, Fournie-Zaluski
et al. 1996). In the central nervous system, AngIII mediates central control of
blood pressure and vasopressin release (Harding, Wright et al. 1994; Song, Wilk
et al. 1997). However, AngIII was catabolized metabolically five times faster than
Ang II because it is very sensitive to degradation by the enzyme aminopeptidase
N, which cleaves the N-terminal arginine, generating AngIV (Zini, Fournie-Zaluski
et al. 1996). AngIV is also short lived and is rapidly converted to inactive
fragments by several peptidases. AngIV mediates its action via the AT4 receptor,
also known as insulin-regulated amino peptidase receptor (IRAP) (Albiston,
McDowall et al. 2001). AT4 receptors are expressed in brain, kidney, heart and
vessels. Its signaling mechanisms are largely unknown, but it influences local
blood flow and is associated with cognitive processes and sensory response (de
Gasparo, Catt et al. 2000)
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1.2.2 Angiotensin, inflammation and cardiovascular disease (CVD)
It has been vastly recognized that RAS overactivation contributes to
various cardiovascular diseases and many clinical studies have demonstrated
that inhibition of the RAS through ACE inhibition or angiotensin receptor blockers
(ARB) is beneficial for patients with CVD. In 1992 it was proved that an ACEinhibitor,enalapril, in combination with the conventional heart failure therapy,
significantly improved the survival of patients with severe congestive heart
failure(Kjekshus, Swedberg et al. 1992). In the Survival of Myocardial Infarction
Long-Term Evaluation (SMILE) study, the risk of myocardial infarction was
reduced by about 37% with ACE inhibitors treatment (Borghi and Ambrosioni
1995) Results from the Heart Outcomes Prevention Evaluation (HOPE) study
revealed that in patients without heart failure ACE inhibition reduced the rates of
death, myocardial infarction, and stroke by 22% without major effects on blood
pressure (Yusuf, Sleight et al. 2000). Furthermore, Losartan Intervention For
Endpoint reduction (LIFE) trial revealed that among patients with hypertension
and left ventricular hypertrophy losartan, an AT1 receptor blocker, significantly
reduced the risk of combined morbidity and mortality compared to a beta-blocker,
atenolol (Dahlof, Devereux et al. 2002).
As a potent pro-inflammatory factor, AngII has been implicated in the
pathogenesis of CVD. Inflammation involves: 1) activation of the endothelium of
blood vessels (permeability) and 2) extravasation (adhesion/transmigration) of
specific leukocyte populations to the site of injury. It has been demonstrated that
AngII acts via AT1 receptors, induces the expression of endothelial adhesive
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molecules including selectins, vascular cell adhesion molecules-1 (VCAM-1),
intercellular adhesion molecules-1 (ICAM-1) and integrins to increase vascular
permeability (Piqueras, Kubes et al. 2000; Pueyo, Gonzalez et al. 2000; Alvarez,
Cerda-Nicolas et al. 2004). AngII also activates COX-2, which generates reactive
oxygen species (ROS) and vasoactive prostaglandins including leukotriene C4
and prostaglandins E2 to induce endothelial dysfunction (Wu, Laplante et al.
2005; Welch 2008). In addition, vascular endothelial growth factor (VEGF), has
been reported to be upregulated by AngII in human VSMCs (Williams, Baker et
al. 1995) and rat heart endothelial cells (Chua, Hamdy et al. 1998).
AngII facilitates the recruitment of infiltrating inflammatory cells into tissues
by stimulating the production of specific cytokine/chemokines. For example,
AngII induces the production of the potent monocyte chemoattractant MCP-1 in
cultured monocytes (Dai, Xu et al. 2007). In spontaneously hypertensive rats
(SHR) elevated AngII level has been associated with increased expression of
MCP-1 and one of its receptors, the C–C chemokine receptor (CCR2) in
macrophages. And AT1 receptor blockade reduced aortic inflammation and
macrophage MCP-1/CCR2 expression in SHR rats (Dai, Xu et al. 2007).
Moreover, in cultured mesangial and vascular smooth muscle cells, Ang II acts
on AT1 receptors to stimulate the expression of the Toll-like receptor 4 (TLR-4),
which promotes cellular oxidative injury, apoptosis and inflammation (Ji, Liu et al.
2009; Lv, Jia et al. 2009). It has been reported recently that AT1 receptor
blockade exerts protective effects against myocardial ischemia and reperfusion
injury by reducing TLR-4 expression and cytokine release (Yang, Jiang et al.
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2009). In addition, AngII also stimulates cytoskeletal rearrangements in T cells
and triggers the release of specific cytokines and chemokines, thus facilitating T
cell recruitment to the sites of inflammation (Jurewicz, McDermott et al. 2007;
Crowley, Frey et al. 2008; Kvakan, Kleinewietfeld et al. 2009).
Taken together, results from both clinical trials and experimental studies
infer a critical role for the RAS in CVD pathogenesis and support the beneficial
effect of AngII inhibition in CVD patients.

1.2.3 Sex Hormones and the RAS
Sex hormones exert differential effects on various components of the RAS
as illustrated in Figure 1.4 (Fischer, Baessler et al. 2002). The overall effect of
physiological concentrations of estrogen is to inhibit the RAS while androgen
generally stimulates the RAS.
Angiotensinogen, the only known precursor of AngII, has an estrogen
response element (ERE) in its gene promoter which markedly stimulates angiotensinogen synthesis (Clauser, Gaillard et al. 1989; Feldmer, Kaling et al. 1991).
Women with oral administration of estrogen replacement therapy exhibit higher
plasma angiotensinogen levels (De Lignieres, Basdevant et al. 1986; Schunkert,
Danser et al. 1997). In rats, renal angiotensinogen mRNA expression was lower
in females compared to males (Ellison, Ingelfinger et al. 1989; Yanes, SartoriValinotti et al. 2009). Furthermore, angiotensinogen mRNA expression was
reduced by castration and increased by administration of exogenous androgen
(Ellison, Ingelfinger et al. 1989). Similarly, renal and hepatic angiotensinogen
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mRNA levels were higher in male than female SHR rats (Chen, Naftilan et al.
1992). Castration of male SHR rats reduced, and testosterone replacement
restored renal and hepatic angiotensinogen mRNA expression (Chen, Naftilan et
al. 1992). Additionally, testosterone exerts considerable stimulatory effects on
angiotensinogen gene expression in a variety of other tissues, including the
adipose tissue (Ming, Sikstrom et al. 1993; Serazin-Leroy, Morot et al. 2000).
In humans, plasma renin levels in postmenopausal women are lower
compared to men and are further decreased by hormone replacement therapy
(Schunkert, Danser et al. 1997; Danser, Derkx et al. 1998). In healthy young
adult population, men exhibit higher ACE activity compared to women (Zapater,
Novalbos et al. 2004). ACE is suppressed in women taking estrogen replacement
therapy (Proudler, Ahmed et al. 1995; Schunkert, Danser et al. 1997). In
experimental models, the circulating concentration of renin is decreased by
estrogen (Oelkers 1996; Brosnihan, Weddle et al. 1997), but increased by
testosterone (Wagner, Metzger et al. 1990; Chen, Naftilan et al. 1992; Kon,
Endoh et al. 1995). Plasma ACE activity and ventricular ACE expression are
significantly higher in male than female mice, and are reduced by castration of
male mice.(Freshour, Chase et al. ; Lim, Retnam et al.)
In studies with estrogen replacement therapy, estrogen appears to down
regulate AT1 receptor mediated effects through reductions in the receptor density
and down-stream activation steps (Nickenig, Baumer et al. 1998; Owonikoko,
Fabucci et al. 2004). In experimental rodents, AT1 receptor densities at heart,
kidney and aortic tissues are decreased by estrogen and increased by
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ovariectomy (Kisley, Sakai et al. 1999; Wu, Maric et al. 2003; Dean, Tan et al.
2005) In contrast, testosterone upregulates the AT1 receptor as castration almost
abolished the AT1 receptor protein in rat epididymis (Leung, Wong et al. 1999).
AT1 receptor protein expression is higher in the renal cortex of male
spontaneous hypertensive rats (Sullivan, Semprun-Prieto et al. 2007). In
addition, elevated contractile responses to AngII in conjunction with greater AT1
receptor mRNA and protein expression were detected in the rat aorta from male
compared to female rats (Silva-Antonialli, Tostes et al. 2004). Renal AT2
receptor expression in female mice is higher than in male mice (Armando,
Jezova et al. 2002; Dean, Tan et al. 2005). It has been reported that castration
increases AT2 expression in male rat bladder while exogenous testosterone
administration reduces its expression (Nakazawa, Tanaka et al. 2007). Most
recently, higher expression of renal ACE2 in female mice has been reported and
ovariectomy reduces ACE2 levels (Ji, Menini et al. 2008).
In summary, while estrogen exerts either stimulatory or inhibitory effects
on different components of RAS, the overall effect of estrogen results in a down
regulation of the RAS. In contrast, testosterone exerts a stimulatory effect on all
major components of the RAS.

1.3.

AngII-induced AAA

1.3.1 Overview
It has been well established that chronic infusion of AngII into
hyperlipidemic mice (LDLR-/- or ApoE-/-) promotes the formation of AAAs
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(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000). Based on the
desired infusion rate (500-1000 ng/kg/min), osmotic mini-pumps are filled with a
pre-determined concentration of AngII and implanted subcutaneously in the
subscapular region of mice to achieve chronic AngII infusion. LDLR-/- or ApoE-/mice are usually fed with a moderately high fat diet (44% kcal from fat) to
augment hyperlipidemia prior to and during AngII infusion. AAAs form at a high
prevalence (80%-100%) with 28 days of chronic AngII infusion (1000 ng/kg/min)
in male mice. AAAs that form from AngII infusion are typically localized in
suprarenal region of the aorta, which is consistent in both ApoE-/- and LDLR-/mice. AngII-induced AAAs are characterized by medial breaks, macrophage
infiltration into media, thrombus formation, extracellular matrix degradation and
adventitia remodeling. In comparison, infusion of AngII into a normolipidemic
background strain, C57BL/6, results in only 10-30% AAA formation in male mice
(Wang 2005). It has been suggested that hyperlipidemia facilitates AngIIinduced AAA formation in mice via upregulating AT1R expression. Multiple
studies also have demonstrated that chronic AngII infusion increased the extent
of atherosclerosis in hyperlipidemic mice (Daugherty, Rateri et al. 2004).
Atherosclerotic lesions are present in the abdominal aortas of mice infused for
very chronic durations with AngII (Saraff, Babamusta et al. 2003). However,
atherosclerosis does not appear to be a requirement for AAA formation. For
example, manipulations have been demonstrated to increase atherosclerosis,
but yet decrease AngII-induced AAAs (Henriques, Huang et al. 2004). In
addition, AngII infusion in nonhyperlipidemic C57BL/6 mice result in modest
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AngII-induced AAA formation, but does not induce atherosclerosis, further
demonstrating that atherosclerosis is not a major contributor to AngII-induced
AAA formation.
As previously discussed, AngII is a potent vasoconstrictor and exerts
potent effects on peripheral resistance. Mice infused with AngII (1000 ng/kg/min)
typically exhibit an increased systolic blood pressure in the range of 20-30 mmHg
(Daugherty, Manning et al. 2000; Manning, Cassis et al. 2002). Although
hypertension has been debated as a risk factor for human AAA formation, AngIIinduces AAA formation in hyperlipidemic mice appears to be independent of
AngII-induced hypertension (Daugherty, Manning et al. 2000; Weiss, Kools et al.
2001). Infusion of norepinephrine to male LDLR-/- mice at the dose that resulted
in a similar hypertensive response as AngII infusion, did not cause AAA
formation (Cassis, Gupte et al. 2009). In addition, co-infusion of antihypertensive
drug (hydralazine) with AngII abolishes the increased blood pressure response
and has no impact on AngII-induced AAA formation (Cassis, Gupte et al. 2009).
AngII infusions activate endogenous RAS and promote aldosterone
release by the adrenal gland. However, aldosterone does not appear to
contribute to AngII-induced AAA as it has been demonstrated that male ApoE-/mice infused with multiple doses of aldosterone failed to generate AAAs (Cassis,
Helton et al. 2005). Furthermore, the aldosterone receptor antagonist
spironolactone had no effect on AngII-induced AAAs. These data demonstrate
that aldosterone is not involved in the development of AngII-induced AAAs.
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1.3.2 Angiotensin receptors in AngII-induced AAAs
As discussed previously, AngII-induced inflammatory response and ROS
production are mediated through AT1 receptor. It has been demonstrated that
co-infusion of AngII and the AT1 receptor antagonist, losartan, completely
prevented AngII-induced AAA formation, demonstrating that AngII infusion
promotes AAA formation through its action on the AT1 receptor (Daugherty,
Manning et al. 2001). AT2 receptor activation by AngII is believed to
counterbalance some of the effects of AT1 receptor. Co-infusion of AngII and the
AT2 receptor antagonist PD123319 enhanced AngII-induced AAA formation in
male ApoE-/- mice (Daugherty, Manning et al. 2001). These results demonstrate
that the AT1 receptor plays a critical role in the development of AngII-induced
AAA while the AT2 receptor protects against AAA formation. Of the two AT1
receptor subtypes in mice, results have demonstrated that, despite the
abundance of AT1b receptor in the aortas, deficiency of the AT1a receptor
subtype completely ablates the development of AngII-induced AAAs (Cassis,
Rateri et al. 2007). Furthermore, AT1aR deficient mice did not exhibit a pressor
response to AngII infusion and AngII-induced atherosclerotic lesion formation
was abolished by AT1aR deficiency (Cassis, Rateri et al. 2007). Collectively,
these data demonstrate that the AT1a receptor is pivotal for AngII-induced AAA
and atherosclerosis formation in hyperlipidemic mice.
Macrophages are abundantly evident in AngII-induced AAA tissues and
atherosclerotic lesions and AT1aR are present on macrophage. To investigate
whether the activation of AT1aR on infiltrating monocytes or resident vascular
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cells contributes to AngII-induced AAA formation, a series of bone marrow
transplantation studies were conducted to create chimeric mice lacking AT1aR
on bone marrow-derived cells. Both wild-type and AT1aR-/- recipients were
irradiated and repopulated with bone marrow-derived cells from mice that was
either wild type or AT1aR deficient. Interestingly, only AT1aR deficient mice
were dramatically protected from AngII-induced AAA and atherosclerosis,
irrespective of the donor genotype. These data indicate that AT1aR in resident
vascular tissue is required for the development of AngII-induced atherosclerosis
and AAAs (Cassis, Rateri et al. 2007).

1.3.3 Mechanistic insights into AngII-induced AAAs
Numerous publications have demonstrated various mechanisms
contributing to the development of AngII-induced AAA (Table 1.1). In agreement
with human AAAs, results from AngII-induced AAAs in mice also support a role
for matrix metalloproteinases (MMPs) in AAA formation. Deficiency of MMP-2 or
MMP-9 completely eliminates calcium chloride induced AAA formation (Longo,
Xiong et al. 2002). Administration of doxycycline, a broad spectrum inhibitor of
MMPs, has been demonstrated to attenuate AngII-induced AAA in LDLR-/- mice
(Manning, Cassis et al. 2003). Metacept-1 (MCT-1), a synthezied histone
deacetylase inhibitor can inhibit MMP-9 mRNA expression in metastatic cancer
cells in vitro (Kim, Lee et al. 1999). Administration of MCT-1 significantly
reduced AAA formation in male ApoE-/- mice (Vinh, Gaspari et al. 2008). Further
evidence for MMP involvement in AngII-induced AAAs comes from recent studies
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demonstrating that deficiency of group X secretory phospholipase (sPLA2) in
ApoE-/- mice reduced AngII-induced AAAs (Zack, Boyanovsky et al. 2010).
Aortas from group X sPLA2 that exhibited reduced AAA formation had blunted
expression of MMP-2, -13 and 14. Interesting recent studies demonstrated that
deficiency of telomerase in bone marrow-derived cells reduced AngII-induced
AAA in LDLR-/- mice, and that these effects were associated with reduced
macrophage MMP-2 expression (Findeisen, Gizard et al. 2010). Collectively,
results from studies using many different approaches support a role for MMP
activation in pivotal cell types in AngII-induced AAAs.
In addition, the plasminogen system has been revealed to contribute to
AngII-induced AAA formation, further supporting an important role of MMPs in
AAA pathogenesis. Plasminogen is converted to plasmin by tissue plasminogen
activator (tPA) or urokinase plasminogen activator (uPA). Plasmin degrades
multiple extracellular matrix (ECM) proteins and activates MMPs. Deficiency of
plasminogen or uPA has been reported to protect mice from AngII-induced AAA
(Deng, Martin-McNulty et al. 2003; Gong, Hart et al. 2008). Plasminogen
activator inhibitor-1(PAI-1) is a major inhibitor of the plasminogen system and
overexpression of PAI-1 has been demonstrated to reduce AngII-induced AAA
formation (Qian, Gu et al. 2008).
Inflammation and macrophage accumulation in AAA regions are
consistent and profound features of AngII-induced AAAs. Monocyte
chemoattractant protein-1 (MCP-1), a prominent chemokine, interacts with its
receptor, CCR2, to invoke macrophage- based immune responses. Deficiency of
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CCR2 markedly attenuated the development of AngII-induced AAAs (Ishibashi,
Egashira et al. 2004). Furthermore it has been revealed that CCR2 expression
on bone marrow-derived cells is required for AngII-induced AAAs formation
(Ishibashi, Egashira et al. 2004; Daugherty, Rateri et al. 2010). Interferon-γ (IFNγ) is a major T-helper type 1(Th1) cytokine and an important mediator of Th1
immune response. In ApoE-/-mice AngII-induced AAA formation was greatly
enhanced with deficiency of interferon-γ (IFN-γ) or IFN-γ-inducible T-cell
chemokine, CXCL10 (King, Lin et al. 2009). Recently, our laboratory has
demonstrated that obesity significantly promotes AngII-induced AAA formation in
nonhyperlipidemic mice. The enhanced AAA formation was associated with
increased macrophage accumulation in periaortic adipose tissue (Police,
Thatcher et al. 2009).
Cyclooxygenase (COX) products, mainly prostaglandin E2 (PGE2), are
classic mediators of inflammation. COX- 2 is expressed in the vessel wall and
macrophages of AAA tissues (Holmes, Wester et al. 1997; Walton, Franklin et al.
1999). In addition, COX-2 expression in human AAA is positively associated with
the extent of macrophage infiltration and the degree of AAA neorevascualrization
(Chapple, Parry et al. 2007). With chronic AngII infusion mice exhibited
increasing levels of COX-2 mRNA in abdominal aortas and deficiency of COX-2
significantly eliminated AngII-induced AAA formation (Gitlin, Trivedi et al. 2007).
Administration of Celecoxib, a COX-2 inhibitor, reduced AngII-induced AAA
incidence and severity in male ApoE-/- mice (King, Trivedi et al. 2006). An
important source of PGE2 in the mouse is microsomal prostaglandin (PG) E2

23

synthase-1 (mPGES-1), which catalyzes the conversion of the COX product
PGH2 to PGE2. It has been demonstrated that mPGES-1 deficiency reduced
oxidative stress, aortic MMP-2 activity and markedly attenuated AngII-induced
AAA formation in LDLR-/- mice (Wang, Lee et al. 2008). Moreover, recent studies
demonstrated that deletion of the EP4 receptor on bone marrow-derived cells
enhanced AngII-induced AAAs in LDLR-/- mice, supporting a protective effect of
PGE2 through the EP4 receptor (Tang, Shvartz et al. 2010).
Similar to COX enzymes, lipoxygenases also produce a variety of
bioactive lipids derived from arachidonic acid. For example, 5-lipoxygenase (5LO) catalyzes the generation of Leukotriene B4, which exerts its effects through
binding to its G protein coupled receptor, BLT-1. Deficiency of BLT-1 reduced
AngII-induced AAAs in ApoE-/- mice (Ahluwalia, Lin et al. 2007). However, a
recent study has demonstrated that both genetic deficiency and pharmacological
inhibition of 5-LO failed to influence the AngII-induced AAAs in ApoE-/- mice
(Cao, Adams et al. 2007). Thus, whether 5-LO signaling cascade contributes to
AAA pathogenesis remains under debate.
Human AAA tissues exhibit increased superoxide anion (O2-), hydroxyl
radical and reactive nitrogen species compared to normal aortic tissue (Miller,
Sharp et al. 2002). As discussed previously, AngII acts via AT1 receptors to
activate NADPH oxidase and produce O2- in cultured vascular smooth muscle
cells (Griendling, Minieri et al. 1994). NADPH oxidase is a primary source of
ROS in the vasculature. Oxidative stress can regulate inflammation, MMP
activation, and vascular smooth muscle cell apoptosis, thus influencing AAA
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development. Dietary enrichment of vitamin E, an antioxidant, has been shown to
attenuate AngII-induced AAA formation in ApoE-/- mice (Gavrila, Li et al. 2005).
In contrast, a recent study found no effect of dietary enrichment of vitamins E and
C on AngII-induced AAA rupture in aged ApoE-/- mice (Jiang, Jones et al. 2007).
However, it has been demonstrated that deficiency of p47phox, a cytosolic
subunit of NADPH oxidase, decreases aortic macrophage, aortic MMP-2 activity
and greatly reduced AngII-induced AAA formation in male ApoE-/- mice
(Thomas, Gavrila et al. 2006). In addition, deficiency of NOX1, a transmembrane
subunit of NADPH oxidase, has been reported to attenuate AngII-induced AAA in
C57BL/6 mice (Gavazzi, Deffert et al. 2007). Recently, deficiency of cyclophilin,
an oxidative stress response mediator, was demonstrated to ablate AngIIinduced AAA formation in ApoE-/- mice (Satoh, Nigro et al. 2009). Overall, these
findings suggest a potential role of and oxidative stress and NADPH oxidase in
the development of AngII-induced AAA.
Initial studies demonstrated that administration of neutralizing antibody to
TGF-β to ApoE-/-/Cxcl10-/- mice decreased AngII-induced aortic dilation (King,
Lin et al. 2009). However, recent studies demonstrated that inhibition of TGF-β
has been reported to enhance inflammation and profoundly increase aortic
dissection in AngII infused C57BL/6 mice (Wang, Ait-Oufella et al. 2010). The
role of TGF-β in AngII-induced AAAs, as well as human AAA, is unclear.
SMC apoptosis is another evident pathological features frequently
observed in AAA tissues. Administration of nonspecific caspase inhibitor was
reported to reduce SMC apoptosis, medial inflammation and AngII-induced AAA
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formation (Yamanouchi, Morgan et al. 2010). Several studies targeting
intracellular signaling pathways have provided further mechanistic insights in
AngII-induced AAAs. It has been reported that Fasudil, a Rho-kinasse inhibitor,
reduces AngII-induced AAAs formation in ApoE-/- mice by inhibiting apoptosis
and proteolysis (Wang, Martin-McNulty et al. 2005). Administration of a JNK
inhibitor, SP600125, attenuated the aneurysm development in CaCl2 induced
AAA mouse model (Yoshimura, Aoki et al. 2005). In addition, when SP600125
was chronically administered for 8 weeks after 4 weeks AngII infusion, the
luminal diameters of formed AngII-induced AAAs showed a significant 18%
reduction and there was no change in aortic diameter of control mice
administered with vehicle (Yoshimura, Aoki et al. 2005). So far his is the only
animal study that exhibits AAA regression with pharmacologic intervention.
Further studies are required to confirm these findings and elucidate the
mechanisms of AAA progression/regression. The investigation of factors and
mechanisms influencing AAA expansion and progression may guide us to new
drug targets and other nonpharmaceutical interventions for AAA treatments.
A feature of human AAAs that has been recently explored in AngIIinduced AAAs is neovascularization to support continued aneurysm growth and
progression. ApoE-/- mice administered human recombinant vascular
endothelial growth factor (VEGF) exhibited increased incidence and size of
AngII-induced AAAs (Choke, Cockerill et al. 2010). Studies in our laboratory
demonstrated that weight loss in obese mice decreased adventitial
neovascularization and prevented continued growth of established AAAs (Police,
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Putnam et al. 2010). These studies suggest that neovasculization is an
important mechanism contributing to continued progression of AngII-induced
AAAs.

1.3.4 Gender in AngII-induced AAAs
Similar to the human condition, male mice are much more susceptible to
AngII-induced AAA formation. The AngII-induced AAA incidence of male mice is
4-5 fold higher compared to that of females (Manning, Cassis et al. 2002;
Henriques, Huang et al. 2004). Interestingly, AngII-induced atherosclerosis and
hypertension are similar between males and females despite the striking gender
difference in AAA formation. Multiple studies have been conducted to investigate
if estrogen exerts some protective effects in female mice to limit AngII-induced
AAA formation. Martin-McNulty et al. demonstrated that administration of 17beta estradiol decreased AngII-induced AAA and atherosclerosis in male ApoE-/mice (Martin-McNulty, Tham et al. 2003). These reductions were associated with
decreased levels of pro-inflammatory and adhesion molecules. However, our
laboratories have reported that elimination of endogenous estrogen by
ovariectomy of female ApoE-/- does not alter AngII-induced AAAs or
atherosclerosis (Henriques, Huang et al. 2004). Notably, orchiectomy of male
ApoE-/- mice markedly reduced AngII-induced AAA formation, resulting in a
similar AAA incidence as that of female mice (Henriques, Huang et al. 2004).
Furthermore, AngII-induced AAA formation in castrated male mice was fully
restored by exogenous androgen, dihydrotestosterone (DHT) (Henriques, Zhang
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et al. 2008). Interestingly, even female ApoE-/- mice responded to DHT and
exhibit a 3-fold increase in AngII-induced AAA formation (Henriques, Zhang et
al. 2008). As summarized in Table 1.2, all these results demonstrate that
androgen is a primary mediator of gender difference in AngII-induced AAA
formation.

1.3.5 Gender in elastase-induced AAAs
In vasculature elastin fibers are crucial for the maintenance of structural
integrity of blood vessels. Progressive destruction of structural matrix proteins,
particularly elastin and collagen, is considered as one of the most important
pathogenesis characteristics in human AAAs. First described in rats, transient
intraluminal perfusion of abdominal aortas with porcine pancreatic elastase
provides another widely used animal model of AAAs (Anidjar, Salzmann et al.
1990; Anidjar, Dobrin et al. 1992; Anidjar, Dobrin et al. 1994). Briefly, a segment
of infrarenal abdominal aorta is isolated by a distal suture and a perfusion
catheter is introduced at the iliac bifurcation. Porcine pancreatic elastase is
instilled into the isolated segment of infrarenal abdominal aorta for 5 minutes at
100 mmHg pressure before restoration of flow. This transient intraluminal
infusion of elastase induces mild aortic dilation immediately after the perfusion.
Aortic diameter remains stable for up to 7 days followed by a rapid and significant
dilation of the abdominal aorta. AAAs, which are defined by at least 100%
increase in aortic diameter over the normal (pre-perfusion) aortas, typically form
by day 14. The development of AAAs in this elastase perfusion model is
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associated with transmural aortic wall infiltration by mononuclear phagocytes,
increased local production of MMPs and massive destruction of the medial
elastic lamellae (Thompson, Curci et al. 2006).
Recently, the application of this elastase model to mice have assisted
investigators identify and study various mediators of AAA formation. For
example, administration of doxycycline, a broad-spectrum inhibitor of MMPs,
significantly attenuated the development of elastase-induced AAA formation
(Bartoli, Parodi et al. 2006). In agreement to the findings in AngII-induced AAA
model, deficiency of MMP-9 has been shown to totally ablate elastase-induced
AAA formation (Pyo, Lee et al. 2000). In contrast, deficiency of MMP-12, alone
or with MMP-9 deficiency, did not influence the occurrence of elastase-induced
AAAs (Pyo, Lee et al. 2000). Smoking, as a primary risk factor of human AAA,
also significantly enhanced the development of elastase-induced AAAs (Buckley,
Wyble et al. 2004). Interestingly, inhibition of RAS by AT1 blocker administration
has been demonstrated to suppress elastase-induced AAAs formation,
suggesting RAS also contribute to the development of AAA in the elastase
perfusion model (Fujiwara, Shiraya et al. 2008).
As summarized in Table 1.2, elastase-induced AAA model also exhibits
gender difference, similar to AngII-induced AAA model. For example, male rats
had larger AAAs and higher AAA incidence than female rats (Ailawadi, Eliason et
al. 2004). Male rat aortas showed more significant macrophage infiltrates and
increased MMP-9 production and activity (Ailawadi, Eliason et al. 2004). In
addition, male rats demonstrated smaller aneurysms, less
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macrophage/neutrophil infiltrate and MMP-9 when treated with estradiol or
tamoxifen, a selective estrogen receptor modulator (Ailawadi, Eliason et al. 2004;
Grigoryants, Hannawa et al. 2005). Ovariectomized female rats exhibited a
higher aneurysm dilatation rate and significantly higher MMP-2 and MMP-9
expressions compared with sham-operated control females (Cho, Woodrum et al.
2009; Wu, Zhang et al. 2009). Exogenous estrogen administration decreased
aneurysm dilatation rate and MMPs expression in ovariectomized females (Cho,
Woodrum et al. 2009; Wu, Zhang et al. 2009). It has been demonstrated that
male rats shows higher MMP2 in aortic smooth muscle cells and in vivo estrogen
exposure greatly decreases male aortic MMP2 production to levels seen in the
female aorta (Woodrum, Ford et al. 2009). These data suggest an important
protective role of estrogen in the development of elastase-induced AAAs.
Furthermore, orchiectomized male rats had significantly smaller AAAs compared
with sham control males and exogenous androgen administration significantly
increased elastase-induced AAAs dilation in castrated male rats (Cho, Woodrum
et al. 2009). It suggests that, in agreement to the observations in AngII-induced
AAAs, androgen contributes to the pathogenesis of AAAs in elastase perfusion
model. However, exogenous androgen had no effect on the development of
elastase-induced AAA in female rats (Cho, Woodrum et al. 2009). Overall, these
studies implicate a definitive protective role of estrogen and suggest a likely
contribution of androgen in elastase-induced AAAs.
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1.4

Androgen
In males, androgens are essential for the development and function of the

testes, maturation of secondary sexual characteristics, masculinization of the
bone-muscle apparatus, libido, and stimulation of spermatogenesis.
Testosterone and its more active metabolite, DHT, are the key androgens
responsible for the development of male genitalia in utero as well as secondary
sex characteristics during puberty. In adulthood, androgens remain essential for
the maintenance of male reproductive function and sexual behavior. The primary
circulating androgen in males is testosterone. The site of testosterone production
in the testis is the Leydig cell. Both synthesis and secretion of testosterone are
under regulation of pituitary luteinizing hormone (LH) and local factors (Lei et al.
2001; Sriraman et al. 2005). It has been reported that in women androgens play
a role in regulating libido, energy, muscle and bone strength (Schneider 2003;
Bolour and Braunstein 2005).
Like all steroid hormones, testosterone is derived from cholesterol. This
transformation goes through different enzymatic steps in which the side chain of
cholesterol is shortened through oxidation. The complete pathway for
testosterone synthesis is depicted in Figure 1.5. The rate limiting step in the
synthesis of testosterone is the cleavage of cholesterol to pregnenalone, which is
catalyzed by the P450-linked side chain cleaving enzyme (P450scc) found in the
mitochondria of steroid producing cells. Testosterone regulates its own synthesis
through a negative feedback loop which regulates the secretion of follicle
stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary and
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gonadotropin releasing hormone (GnRH) by the hypothalamus. Low levels of
circulating testosterone decrease the inhibition on GnRH synthesis, leading to
elevated FSH and LH levels, resulting in increased testosterone synthesis.

1.4.1 Metabolism of androgen
Testosterone can be also converted to another two important hormones:
DHT through 5α-reduction and estradiol through aromatization. While only a
small amount of circulating testosterone (<5%) gets converted to active
metabolites, which typically occurs at the tissue level, this process can amplify
and diversify testosterone function (Liu, Death et al. 2003). Conversion of
testosterone to DHT is irreversibly catalyzed by the enzyme 5α-reductase. Like
testosterone, DHT binds to androgen receptors and amplifies testosterone
action. Importantly, DHT binds with higher molar potency due to greater affinity
and a slower dissociation rate (Wilbert, Griffin et al. 1983; Grino, Griffin et al.
1990). Furthermore, DHT activates gene expression more efficiently than
testosterone (Deslypere, Young et al. 1992). Therefore, testosterone, through
conversion to DHT, can exert more potent effects in tissues expressing 5αreductase compared to tissues where the enzyme is not expressed. Two forms of
the 5α-reductase enzyme have been identified: type I, is predominantly found in
nongenital skin and the liver, and type II, which is primarily located in urogenitals
of men and genital skin in both men and women. Both forms of the enzyme have
been located in vascular tissue based on immunoreactivity (Eicheler, Tuohimaa
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et al. 1994; Eicheler, Dreher et al. 1995) and enzymatic activity (Milewich, Kaimal
et al. 1987; Fujimoto, Morimoto et al. 1994).
Testosterone actions are diversified by its conversion to estradiol and the
subsequent binding to the ER. The conversion reaction is irreversible and
catalyzed by the enzyme aromatase (CYP19). Aromatase is expressed in many
tissues, particularly in the liver and adipose tissue. Additionally, aromatase gene
expression, protein levels and enzymatic activity have been detected in vascular
tissue, particularly in the endothelium and smooth muscle (Diano, Horvath et al.
1999; Harada, Sasano et al. 1999; Murakami, Harada et al. 2001). Approximately
85% of circulating estradiol in men is derived from testosterone conversion by
aromatase, with the remainder being secreted by the leydig cells of the testes
(Aiman, Griffin et al. 1979).

1.4.2 Androgen receptor
Like other steroid hormones, androgens mediate their biological action
through binding to androgen receptors (AR), members of the steroid hormone
receptor superfamily. AR is widely expressed in many various tissues (Wilson
and McPhaul 1996). In the vasculature, ARs are expressed in various cell types,
including endothelial cells, vascular smooth muscle cells, macrophages, and
platelets. Interestingly, it has been demonstrated that males exhibits higher AR
density in vascular tissue compared to females (Higashiura, Mathur et al. 1997).
In macrophage, AR density has been reported to be 4-fold higher in males
compared to females (McCrohon, Death et al. 2000; Ng, Quinn et al. 2003).
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AR is produced from a single-copy gene located on the X-chromosome
(Brown, Goss et al. 1989; Kokontis and Liao 1999). The genomic DNA encoding
AR spans about 90 kb and codes for a 2,757-base pair open reading frame
within a 10.6-kb mRNA and the coding sequence of human AR gene consists of
eight exons (Roy, Tyagi et al. 2001). The AR is a ligand-inducible transcription
factor which regulates the expression of target genes in response to ligand
binding (Heinlein and Chang 2002). Similar to other members of the nuclear
receptor superfamily, AR has four major functional regions; the N-terminal
transactivation domain (TAD), a central DNA-binding domain (DBD), a C-terminal
ligand-binding domain (LBD), and a hinge region connecting the DBD and LBD
(Mangelsdorf, Thummel et al. 1995). The DBD of the AR exhibits a high degree
of amino acid sequence homology to other steroid hormone receptors including
the glucocorticoid receptor (GR), the progesterone receptor (PR), and
mineralocorticoid receptor (MR). Consequently, the four receptors recognize very
similar hormone response elements (HREs). The transcriptional activity of AR is
mediated by a constitutively active activation function (AF-1) originating in the Nterminal TAD and a ligand-dependent activation function (AF-2) in the LBD
(Gronemeyer and Laudet 1995). The hinge region was initially considered to be
a flexible linker between the DBD and LBD. However, this region has been
revealed to be involved in DNA binding as well as AR dimerization and to
attenuate transcriptional activity of the AR (Wang, Lu et al. 2001; Haelens,
Tanner et al. 2007).
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1.4.3 Mechanism of action of ARs
The unbound AR is typically found in the cytoplasm of target cells, where
it is sequestered as a multi-protein complex with heat shock proteins and
immunophillins (DeFranco 1999). In the absence of the agonist, the ligandbinding domain (LBD) at the carboxyl terminus of the AR prevents the
transactivation function of the N-terminal domain. Deletion of the LBD makes the
receptor constitutively active by allowing its interaction with coactivator proteins
(Roy, Tyagi et al. 2001). Upon ligand binding, a conformational change occurs
which causes the dissociation of heat shock proteins, dimerization and
translocation to the nucleus, thus activating androgen response elements (AREs)
(Roy, Tyagi et al. 2001). Within the nucleus, the AR scans the genome for AREs
in the promoters and enhancers of target genes. ARE is a 15-bp palindromic
sequence which consist of two hexameric half-sites arranged as inverted repeats
with a 3-bp spacer. Once bound to the hormone response element of a target
gene, the receptor dimer recruits and interacts with classes of co-regulators and
key transcriptional machinery to induce or inhibit transcription of a particular
target gene. Both testosterone and DHT bind to the LBD of the AR, allowing the
receptor complex to bind to specific responsive genes and stimulate the
expression of those target genes (Brinkmann and Trapman 2000). However, if
the AR is antagonist bound, this receptor dimer binds to the ARE and recruits corepressors such as N-CoR and SMRT and, indirectly, histone deacetylases,
leading to transrepression of target genes (Aarnisalo, Palvimo et al. 1998;
Slagsvold, Kraus et al. 2001; Kinyamu and Archer 2004).
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As described previously, one critical AR-mediated transcription through
co-regulators is epigenetic chromatin modification (Heemers and Tindall 2007).
It involves two primary types of coregulatory complexes (Kinyamu and Archer
2004). The first is the adenosine triphosphate (ATP)-dependant chromatin
remodeling complexes, such as the switch/sucrose nonfermenting (SWI/SNF)
complex . The ATP-dependent chromatin remodeling complexes primarily
mediates the opening of chromatin (Cartwright, Hertzberg et al. 1983; Gross and
Garrard 1988), facilitates formation of nucleosome arrays, homologous strand
pairing and DNA transcription(Lusser and Kadonaga 2003). The second type of
coregulatory is histone modifiers such as histone deacetylases (HDAC), histone
acetyltransferases (HAT) and histone methyltransferases (HMT). Some
androgen receptor coactivators, such as CBP/p300 and LSD1, mediate
transcription through their histone motifying enzymatic activities (Baek, Ohgi et
al. 2006; Kahl, Gullotti et al. 2006). Modification of a histone residue changes the
net charge of the nucleosome, which results in loosening or tightening of the
DNA-histone interactions, thus affecting transcription efficiency. Histone
modifications mediate transcription through acetylation/deacetylation of lysine
residues on histone H4, and through methylation of histone lysine and arginine
residues (Strahl and Allis 2000; Kraus and Wong 2002).
Furthermore, androgen also exert non genomic effects of androgens
which are faster than genomic effect through AR (Losel and Wehling 2003). Most
nongenomic effects involve a membrane receptor, and putative binding sites are
described for all major classes of steroids, including androgens (Heinlein and
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Chang 2002). In general, nongenomic androgen effects involve the rapid
induction of conventional second messenger signal transduction cascades,
including increases in cytosolic calcium and activation of protein kinase A, protein
kinase C, and MAPK, leading to diverse cellular effects. Nongenomic androgen
action is insensitivity to inhibition of RNA and protein synthesis and classic AR
antagonists (Liu, Death et al. 2003).

1.4.4 Androgens and cardiovascular disease (CVD)
In general, men are more than twice as likely as women to die from
coronary heart disease in all populations and male gender is considered to be an
independent risk factor for CVD (British Heart Foundation Statistics Database
1998). Androgens, specifically testosterone, are believed to be associated with a
higher risk of CVD in men (Foreman 1986; Kalin and Zumoff 1990). Increased
premature cardiovascular events have been observed in male athletes using
high levels of anabolic steroids (Bagatell and Bremner 1996). Researchers in
recent years have turned with increasing interest in elucidating the role of
androgen on the development of CVD. Interestingly, a 10 year-follow up cohort
study has revealed that testosterone levels are not different between men who
develop CVD and their healthy cohorts (Arnlov, Pencina et al. 2006). In large
prospective cohort studies (Smith, Ben-Shlomo et al. 2005; Arnlov, Pencina et al.
2006), baseline testosterone levels had not been associated with incidence of
cardiovascular events. These data do not support the hypothesis that androgen
increases CVD risk.
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In addition, a retrospective data analysis on male veterans showed an
association of low androgen levels with increased mortality (Shores, Matsumoto
et al. 2006). In a large cohort study older men with testosterone insufficiency
were found to have an increased risk of death over 20 years of follow-up
(Laughlin, Barrett-Connor et al. 2008). It has been well demonstrated that men
with coronary artery disease had a higher prevalence of hypoandrogenemia
(Eckardstein and Wu 2003; Wu and von Eckardstein 2003; Pinthus,
Trachtenberg et al. 2006). In many studies ultrasonography was used to evaluate
vessel intima thickness, a marker used to investigate the progression of
atherosclerosis. Using this method, plasma testosterone levels were negatively
correlated with atherosclerosis progression (Demirbag, Yilmaz et al. 2005).
Rosano et al examined 129 patients with CVD symptoms and found a clear
inverse relationship between the degree of CAD and plasma testosterone levels
(Rosano, Sheiban et al. 2007). Furthermore, a number of studies that correlated
intima-media thickness to endogenous androgen levels seem to have confirmed
similar findings. As reviewed by Manolakou et al, in most clinical studies,
subjects with high endogenous testosterone levels corresponded with statistically
significant lower atherosclerosis compared to subjects with lower testosterone
(Manolakou, Angelopoulou et al. 2009). Notably , this finding persisted in both
genders, including men (van den Beld, Bots et al. 2003; Muller, van den Beld et
al. 2004; Makinen, Jarvisalo et al. 2005), premenopausal and postmenopausal
women (Bernini, Sgro et al. 1999; Golden, Maguire et al. 2002; Debing, Peeters
et al. 2007) . The cardiovascular protective effect of endogenous androgen
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observed in premenopausal women suggest it involves direct androgen action,
independent of conversion to estrogen., All these findings demonstrate low
endogenous testosterone correlates positively with higher prevalence CVD and
suggest that endogenous androgen exerts protective effects from CVD
development.
The effects of exogenous androgen on CVD pathogenesis are less well
studied. Testosterone administration among 293 female-to-male transsexuals
showed no increase in cardiovascular deaths in a 20-year follow up study (van
Kesteren, Asscheman et al. 1997). In addition, testosterone supplementation in
low to normal levels has mostly been found to be beneficial to cardiovascular
system in hypogonadal men. Several studies have reported beneficial actions of
exogenous testosterone therapy on coronary blood flow and exercise-induced
myocardial ischaemia in men (Malkin, Pugh et al. 2004; Malkin, Jones et al.
2009). However, exogenous testosterone administration in supraphysiological
doses, such as anabolic steroid abuse, seems to have adverse effects such as
development of myocardial infarction, left ventricular hypertrophy, hypertension,
arrhythmia, cardiac failure, pulmonary embolism, stroke, and sudden death
(Ferrera, Putnam et al. 1997; Karila, Karjalainen et al. 2003; Maravelias, Dona et
al. 2005). Androgen therapy is used as a performance enhancer in women.
However, the role of testosterone role in the development of CAD in women is
still not completely understood. The long-term cardiovascular effects of androgen
replacement therapy in women have not been studied. Thus, further studies are
needed to clarify the exact roles of androgen in the development of CVD in

39

different genders and the knowledge can also help us understand the
mechanisms underlying cardiovascular manifestations in general.

1.4.5 Androgen during development and sex dimorphism
Male sexual differentiation has been revealed to be initiated by the testisdetermining factor SRY, a transcription factor encoded on the Y chromosome
(Sinclair, Berta et al. 1990). By interacting with other factors, SRY induces the
development of testis, which secretes androgen responsible for male secondary
sexual differentiation. The differentiated testis starts to synthesize low level of
testosterone in Leydig cells from day 15 in the rat (El-Gehani, Zhang et al. 1998)
and at 12-17 weeks of pregnancy in humans (Diez d'Aux and Pearson Murphy
1974) In male rats, androgen secretion from the testis leads to 2 perinatal peaks
of plasma testosterone concentration: the first occurs on day 18 of gestation and
the second approximately 2 hour after birth (Weisz and Ward 1980; Corbier,
Edwards et al. 1992). This perinatal androgen surge has been observed in many
other species, such as mice, horses and primates (Corbier, Edwards et al. 1992).
Androgen during embryonic and neonatal life mediates the initial growth and
differentiation of the male reproductive tract, such as the Wolffian ducts,
urogenital sinus, and external genitalia primordial (Bentvelsen, Brinkmann et al.
1995).
Besides the well characterized sexual dimorphism of the reproductive
system, other tissues and organs, including kidney, liver, and brain, have been
reported to exhibits sex differences with regard to expression of certain genes
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(Waxman and Celenza 2003; Wiwi and Waxman 2005; Clodfelter, Holloway et al.
2006). A recent microarray analysis of 23,574 transcripts revealed a much
greater extent of sexual dimorphism in gene expression than previously
recognized. In all the active genes that were tested, sexual dimorphism ranged
from 14% (in the brain) to 70% (in the liver) (Yang, Schadt et al. 2006).
A pioneering study in 1959 demonstrated that female guinea pigs exposed to
prenatal androgen exhibited male-like behaviors (Phoenix, Goy et al. 1959). The
experimental method used by Phoenix et al has been adapted by numerous
investigators in the study of sex differences in the brain and behavior (Becker,
Arnold et al. 2005). In this approach, the short-term exogenous androgen
exposure is imposed upon females prenatally or neonatally, mimicing effects of
perinatal androgen surge in males during development (Motelica-Heino,
Castanier et al. 1988; Corbier, Edwards et al. 1992). As thoroughly reviewed,
exposure of females during the prenatal or neonatal period to androgen has been
used previously to induce male-like, or androgenized, behaviors (Pfaff and
Zigmond 1971; Hrabovszky and Hutson 2002; Wallen 2005). Sexual dimorphism
in the brain may take many forms, including difference in structure (e.g., the size
or number of neurons), connectivity (e.g., axon projection patterns or synapse
number), and neurochemistry (e.g., the expression of neuropeptides,
neurotransmitters or receptors). Previous results indicated that exposure of
females to androgen during development mediates many cellular/molecular
mechanisms, such as apoptosis, cell migration and synaptogenesis, that
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influence neuron numbers, dendrite morphology and neurotransmitter
phenotypes in the brain (Simerly 2002; Foecking, McDevitt et al. 2008).
One of the well-studies sexual dimorphic features in mammalian brain is
cell number. The sex dimorphism may exist either in the total number of cells in a
specific brain region or in the number of cells of a particular phenotype. In many
cases, sex differences in cell number have been attributed to the action of sex
hormones during development, particularly testosterone and testosterone
metabolites such as estradiol (Forger 2006). For example, the bed nucleus of
the stria terminalis (BSNT) is a limbic forebrain structure involved in the control of
sexual behavior, gonadotrophic release, stress and anxiety (Emery and Sachs
1976; Beltramino and Taleisnik 1980). The principal nucleus of the BNST
(BNSTp) is larger in males compared to females across many species including
rats, mice, guinea pigs, and humans (Hines, Davis et al. 1985; Allen and Gorski
1990; Walker, Toufexis et al. 2003). In rodents, the gender difference in BNSTp
volume is attributed to an increased number of cells in males and neonatal
testosterone administration in females elevated the cell number to a similar level
of males (Guillamon, Segovia et al. 1988). Similarly, in spinal nucleus of the
bulbocavernosus (SNB), which is a cluster of motoneurons located in the lumbar
spinal cord, male rodents have more neurons than do females (Breedlove and
Arnold 1980; Wee and Clemens 1987). SNB motoneurons innervate striated
muscles of the perineum that control copulation, including the bulbocavernosus
(BC) and levator ani (LA). Interestingly, these muscles also exhibit marked
sexual dimorphism: the BC is completely absent and the LA is greatly reduced in
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females (Breedlove and Arnold 1980; Wee and Clemens 1987). Neonatal
testosterone was shown to increase SNB motoneuron number and BC/LA
muscle volume (Breedlove and Arnold 1983). During development, over 50% of
neurons initially generated in utero undergo apoptosis in a highly restricted time
window that varies among different regions of the brain (Oppenheim 1991). It
has been well established that cell death contributes to sex dimorphism of cell
numbers in the brain (Forger 2006). For example, perinatal testosterone
administration has been reported to rescue cells in SNB from death (Breedlove
and Arnold 1983). Bax and Bak are pro-apoptotic factors that belong to the Bcl-2
family of apoptosis-regulating proteins. Deficiency of Bax has been reported to
eliminate the gender difference in SNB motoneuron number (Jacob, Bengston et
al. 2005). In addition, the BC and LA muscles were markedly increased in the
female mice with both Bax and Bak deficiency (Jacob, Ray et al. 2008).
These changes in brain neurons of females androgenized during
development have been reported to be permanent and are considered to be
“organizational”, allowing for male-like behaviors that persist to adulthood (Arnold
2009). A recent study in mice demonstrated that the male brain shows higher
extent of chromatin modifications on histone 3, which are associated with both
gene activation and suppression. Moreover, in female brains prenatal
testosterone exposure reversed this dimorphism (Tsai, Grant et al. 2009). These
data suggest that epigenetic mechanisms have been implicated to contribute to
the development of sexual dimorphism in the brain (Tsai, Grant et al. 2009). Most
recently it has been reported that 2 hepatic steroid metabolizing enzymes,
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Cyp2b9 and Cyp2a4, are expressed more abundantly in females compared to
males and neonatal testosterone exposure diminishes these dimorphic gene
expression patterns (Ramirez, Luque et al. 2010). In contrast to studies focused
on reproductive organs and the brain, little is known about developmental effects
of sex hormones on other tissues/organs.
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Table 1.1 Summary of findings in AngII-induced AAAs
Mediator

Application

Mouse
Strain
Gender

Effect on
AAAs

Reference

Inflammation
CCR2 -/-: whole body

ApoE-/-

Male

↓

CCR2 -/-: bone marrow

ApoE-/-

Male

↓

(Ishibashi, Egashira et al.
2004; Daugherty, Rateri et
al. 2010)
(Ishibashi, Egashira et al.
2004)

COX-2 -/-

Hybrid

NS

↓

(Gitlin, Trivedi et al. 2007)

COX-2 inhibition: celecoxib

ApoE-/-

Male

↓

(King, Trivedi et al. 2006)

COX-1 inhibition: SC-560

ApoE-/-

Male

↔

(King, Trivedi et al. 2006)

5-LO -/-

ApoE-/-

Male

↔

(Cao, Adams et al. 2007)

5-LO inhibition: MK-0591

ApoE-/-

Male

↔

(Cao, Adams et al. 2007)

BLT1 -/-

ApoE-/-

NS

↓

(Ahluwalia, Lin et al. 2007)

IFN-γ -/-

ApoE-/-

Male

↑

(King, Lin et al. 2009)

CXCL10-/-

ApoE-/-

Male

↑

TGF-β activity inhibition

C57BL/6

Male

↑

High fat diet induced obesity

C57BL/6

Male

↑

GX sPLA2 -/-

ApoE-/-

Male

↓

(Police, Thatcher et al. 2009)
(Zack, Boyanovsky et al.
2010)

EP4 -/-: bone marrow

LDLR-/-

Male and
Female

↑

(Tang, Shvartz et al. 2010)
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(King, Lin et al. 2009)
(Wang, Ait-Oufella et al.
2010)

Table 1.1 Summary of findings in AngII-induced AAAs (continued)
Mediator

Application

Mouse
Strain
Gender

Effect on
AAAs

Reference

Oxidative Stress
Male

↓

(Thomas, Gavrila et al. 2006)

Male

↓

(Thomas, Gavrila et al. 2006)

mPGES-1 -/-

ApoE-/C57BL/6
(N6)
LDLR-/-

Male

↓

(Wang, Lee et al. 2008)

Cyclophilin A -/-

ApoE-/-

Male

↓

(Satoh, Nigro et al. 2009)

Vitamin E

ApoE-/-

Male

↓

(Gavrila, Li et al. 2005)

Vitamins E and C

ApoE-/-

Male

↔

(Jiang, Jones et al. 2007)

HDAC inhibititon: MCP-1

ApoE-/-

Male

↓

(Vinh, Gaspari et al. 2008)

MMP inhibitor: doxycycline

Male

↓

(Manning, Cassis et al. 2003)

NS

↓

(Gong, Hart et al. 2008)

TERT-/- : bone marrow

LDLR-/C57BL/6
(N6)
LDLR-/-

Male

↓

(Findeisen, Gizard et al. 2010)

Caspase inhibitor

ApoE-/-

Male

↓

Rho-kinase inhibition: fasudil

ApoE-/-

Male

↓

(Yamanouchi, Morgan et al.
2010)
(Wang, Martin-McNulty et al.
2005)

JNK inhibition: SP600125

ApoE-/-

Male

↓

(Yoshimura, Aoki et al. 2005)

p47phox -/NOX-1 -/-

Proteases

Plasminogen -/-

Intracellular
signaling
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Table 1.1 Summary of findings in AngII-induced AAAs (continued)

Strain

Gender

Effect
on
AAAs

AT1aR -/- : whole body

LDLR-/-

Male

↓

(Cassis, Rateri et al. 2007)

AT1aR -/- : bone marrow
MR antagonism:
spironolactone

LDLR-/-

Male

↔

(Cassis, Rateri et al. 2007)

ApoE-/-

Male

↔

(Cassis, Helton et al. 2005)

Orchidectomy

ApoE-/-

Male

↓

(Henriques, Huang et al. 2004)

Ovariectomy

ApoE-/-

Female

↔

(Henriques, Huang et al. 2004)

Mouse
Mediator

Application

Reference

RAS
Components

Hormonal

Abbreviations : 5-LO-5-lipoxygenase; AAA-Abdominal aortic aneurysm; Apo-apolipoprotein; AT1aR-angiotensin II type 1a
receptor; BLT1- G-protein coupled receptor for leukotriene B(4); CCR2-chemokine receptor 2; COX-cyclooxygenase;
CXCL10-IFN-γ-inducible T-cell chemoattractant IP-10; EP4-prostaglandin E receptor 4; GX sPLA2-group X secretory
phospholipase; HDAC-histone deacetylase; IFN-γ-interferon γ; JNK-c-Jun N-terminal kinase; LDLR-low-density
lipoprotein receptor; MCP-1-monocyte chemoatractant protein-1; MMP-matrix metalloproteinase; mPGES-1-microsomal
prostaglandin (PG) E2 synthase-1; MR-mineralocorticoid receptor; NS-not specified; TERT-telomerase reverse
transcriptase.

47

Table 1.2 Gender difference in AngII and elastase-induced AAAs.
AAA
model

AngII

Application

gender species

effect on
AAA

Reference

orchiectomy

male

mouse

↓

(Henriques, Huang et al. 2004)

ovariectomy

female

mouse

↔

(Henriques, Huang et al. 2004)

exogenous androgen

male

mouse

↑

(Henriques, Zhang et al. 2008)

exogenous androgen

female

mouse

↑

(Henriques, Zhang et al. 2008)

exogenous estrogen

male

mouse

↓

(Martin-McNulty, Tham et al. 2003)

orchiectomy

male

rat

↓

(Cho, Woodrum et al. 2009)

ovariectomy

female

rat

↑

exogenous estrogen

male

rat

↓

exogenous estrogen

female

rat

↓

(Cho, Woodrum et al. 2009; Wu, Zhang et al.
2009)
(Ailawadi, Eliason et al. 2004; Cho, Woodrum et
al. 2009)
(Cho, Woodrum et al. 2009; Wu, Zhang et al.
2009)

exogenous androgen

male

rat

↑

(Cho, Woodrum et al. 2009)

exogenous androgen

female

rat

↔

(Cho, Woodrum et al. 2009)

elastase
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Angtiontensinogen
renin

Ang II (1-10)

ACE2

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His -Leu

ACE

ACE

AT1R
Vasoconstriction
↑Inflammation
↑ Cell growth

Ang 1-9
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His

ACE2

AngII (1-8)

Ang 1-7
Asp-Arg-Val-Tyr-Ile-His-Pro

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
Aminopeptidase A

AT2R
Vasodilation
↓Inflammation
↓ Cell growth

AngIII (2-8)
Arg-Val-Tyr-Ile-His-Pro-Phe
Aminopeptidase N

AngIV (3-8)
Val-Tyr-Ile-His-Pro-Phe
Aminopeptidase

Inactive metabolites

Figure 1.1 Current RAS with biologically active peptides highlighted in blue.
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Figure 1.2 Signaling of the AT1 receptor.
Abbreviations: Gq, G protein; PLC, PLD, PLA2, phospholipase C, D, and A2,
respectively; IP3, inositol-1, 4, 5-triphosphate; DAG, diacylglycerol; PKC, protein
kinase C; MAP, mitogen activated protein; JAK, Janus kinase; STAT, signal
transducers and activators of transcription. Adapted from Dinh et al Clinical
Science 100(5): 481–92 (2001).

50

Figure 1.3 Signaling of the AT2 receptor.
Abbreviations: cGMP, cyclic guanosine monophosphate; Gi, inhibitory G protein;
PTP, protein tyrosine phosphatase; PP2A, serine/threonine phosphatase 2A;
ERK, extracellular signal-regulated kinase; NO, nitric oxide. Adapted from Dinh et
al Clinical Science 100(5): 481–92 (2001).

51

Figure1.4 Regulation of the renin angiotensin system (RAS) by male and female
sex hormones. The overall effect of estrogen is to tune down the RAS while
androgen tends to stimulate the RAS. Adapted from Fischer et al Cardiovascular
Research 53: 672-677.
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Figure 1.5 The pathway leading to synthesis of testosterone from cholesterol and
its subsequent metabolism to other hormones. Adapted from
http://www.hemingways.org/GIDinfo/hrt_intro.htm.
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CHAPTER IA. STATEMENT OF THE PROBLEM

Abdominal aortic aneurysms (AAA) are commonly found in 4% to 8.5% of
men and 0.5% to 1.5% of women in the population over the age of 60 (Wilmink,
Quick et al. 1999; Lawrence-Brown, Norman et al. 2001; Ashton, Buxton et al.
2002; Cornuz, Sidoti Pinto et al. 2004; Palombo, Lucertini et al. 2010). Recently it
has been estimated that AAA prevalence in the United States are 1.1 million
people between the ages of 50 to 84 (Kent, Zwolak et al. 2010). AAA is the 13th
leading cause of the death and causes at least 15,000 deaths each year in the
United States (Gillum 1995). Male gender is a strong independent risk factor for
developing AAAs. Men exhibit greater incidence and severity of AAA compared
to women. In recent decades AAA incidences and ruptures have been escalating
in western societies, especially in male gender (Best, Price et al. 2003; Acosta,
Ogren et al. 2006). Unfortunately, so far there is no effective pharmacological
intervention to treat AAA.
Our laboratories have established that chronic infusion of AngII into
hyperlipidemic mice induces the development of AAA the effect of AT1aR
(Daugherty, Manning et al. 2000; Cassis, Rateri et al. 2007). Similar to human
condition, AngII-induced AAAs also exhibit profound gender differences. The
AngII-induced AAA incidence of male mice is 4-5 fold higher compared to that of
females (Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). Our
laboratory has previously demonstrate that orchidectomy of male ApoE-/- mice
markedly reduces AngII-induced AAA formation while ovariectomy of female
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ApoE-/- does not have any influence on aneurysm formation (Henriques, Huang
et al. 2004). Notably, exogenous androgen administration restored AngII-induced
AAA formation in castrated male mice and significantly enhanced the
development of AAA in female mice (Henriques, Zhang et al. 2008). All these
results demonstrate that androgen is a primary mediator of gender difference in
AngII-induced AAA formation. However, mechanisms underlying the effects of
androgen to mediate enhanced susceptibility to AngII-induced AAAs have yet to
be defined.
Therefore, the purpose of the present research was to determine how
androgens during different periods of life span promote AngII-induced AAA
formation in hyperlipidemic mice. We hypothesized that androgen stimulate
AT1aR expression in aortas to confer a higher prevalence of AngII-induced AAAs
in male mice. We established that androgen increases SMC AT1aR expression
in the vasculature to stimulate AngII-induced AAA formation in adult male and
female mice. We also investigated the effect of short-term exogenous androgen
exposure during development on aortic AT1aR expression and AngII-induced
AAA formation in adult female hyperlipidemic mice. Moreover, we defined how
castration influences the progression of established AngII-induced AAAs in male
mice.

Copyright © Xuan Zhang 2011
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CHAPTER IB. HYPOTHESIS

Androgen promotes angiotensin receptor type 1a expression on vascular
smooth muscle cells to confer higher angiotensin II-induced AAA formation in
male hyperlipidemic mice.

To test this general working hypothesis, the following goals were outlined:
Goal 1: To examine the role of androgen on the progression of established
angiotensin II-induced AAA.
Hypothesis 1: Removal of endogenous androgen will decrease the
progression of established angiotensin II-induced AAA.
Specific Aim 1: To determine the effect of castration on the
progression of established angiotensin II-induced AAA in male
ApoE-/- mice.

Goal 2: To examine the role of androgen on the expression of aortic smooth
muscle angiotensin receptor type 1a.
Hypothesis 2: Androgen will stimulate aortic smooth muscle angiotensin
receptor type 1a expression to promote higher angiotensin II-induced AAA
formation.
Specific Aim 2: To determine the effect of androgen on aortic
angiotensin receptor type 1a expression and the effect of smooth
muscle angiotensin receptor type 1a deficiency on angiotensin II-
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induced AAA formation in female hyperlipidemic mice administered
exogenous androgen.

Goal 3: To examine the role of androgen during development on the expression
of aortic smooth muscle angiotensin receptor type 1a and angiotensin II-induced
AAA in adult mice.
Hypothesis 3: Administration of androgen during development in female
mice will increase aortic smooth muscle angiotensin receptor type 1a and
promote higher angiotensin II-induced AAA formation in adulthood.
Specific Aim 3: To determine the effect of androgen administration
in neonatal female mice on aortic smooth muscle angiotensin
receptor type 1a expression and angiotensin II-induced AAA
formation in adulthood.

Copyright © Xuan Zhang 2011
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CHAPTER II. SPECIFIC AIM 1

Determine the effect of castration on the progression of established
angiotensin II (AngII)-induced AAAs in male apolipoprotein E (ApoE) -/- mice.

2.1 Summary
Previous studies demonstrated that castration profoundly reduces AngIIinduced AAA incidence in males while exogenous androgen administration
restores AAA formation in castrated male mice. These results demonstrated that
androgen is a primary regulator of AngII-induced AAA formation in male mice. In
this study, we sought to determine the effect of castration on the progression of
established AngII-induced AAAs, with the hypothesis that removal of androgen
will slow AAA progression and reduce the risk of aneurysmal rupture.
Male ApoE-/- mice were infused with AngII for 4 weeks to induce AAA
formation. Mice with AAAs were identified by ultrasound. Mice with AAAs of
different sizes were evenly distributed into groups that were sham-operated or
castrated. After surgery, mice from both groups were then chronically infused for
an additional 8 weeks with AngII. During prolonged AngII infusion, mice from
sham control groups exhibited marked progressive lumen dilation beyond that
observed following 1 month of AngII infusion. Castration significantly decreased
abdominal aortic lumen diameters of male mice chronically infused with AngII
(day 56, 1.74 ± 0.05 vs 1.50 ± 0.04 mm; day 70, 1.87 ± 0.05 vs 1.62 ± 0.04 mm;
day 84, 1.88 ± 0.05 mm vs 1.63 ± 0.04 mm; P<0.05; sham vs castration,
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respectively). However, maximal external abdominal aortic diameters of cleaned,
excised AAAs were not significantly different between sham-operated and
castrated mice. AngII-induced atherosclerosis was not altered by castration.
In conclusion, these data demonstrate that removal of endogenous
androgen has a significant impact on the luminal dilation of established AngIIinduced AAA, but does not influence the aortic diameter of AAAs.
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2.2 Introduction
The natural history of AAA progression is gradual expansion of aortic
diameters obtained by ultrasound with increased risk of rupture as AAA size
increases. Ruptured AAAs are a leading cause of death in western countries and
result in at least 15,000 deaths per year in the United States. Based on current
clinical practice guidelines, the only effective therapeutic option to prevent AAA
rupture is open repair or endovascular surgery if AAA size (by ultrasound)
exceeds 5-5.5 cm. Patients with small AAAs are usually excluded from AAA
surgical repairs and so far no pharmaceutical drugs have been proven to
markedly reduce AAA size progression and/or prevent ruptures of small AAAs. It
has been generally acknowledged that AAA rupture risk increases while
aneurysms are growing and expanding. The mean growth rate of small AAAs is
2.6 to 3.2 mm per year (Lederle, Wilson et al. 2002). It has been demonstrated
that AAA expansion rate is positively associated with cigarette smoking and
aneurysm diameter at baseline (Lindholt, Heegaard et al. 2001; Brady,
Thompson et al. 2004) and negatively associated with diabetes and peripheral
arterial diseases (Brady, Thompson et al. 2004). Therefore, it is highly likely that
interventions that slow AAA progression will decrease the risk of AAA rupture in
patients and immensely improve the outcome of AAA medical treatment.
The renin angiotensin system (RAS) has been demonstrated to be
important in AAA pathogenesis in experimental models, and is gaining
importance as a contributor to human AAA pathology. Chronic infusion of AngII
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induces AAA formation in hyperlipidemic male mice (Daugherty and Cassis 1999;
Daugherty, Manning et al. 2000). Enhanced AngII levels and AngII producing
enzymes, namely chymase and ACE, have been detected in human AAA tissues
(Nishimoto, Takai et al. 2002; Tsunemi, Takai et al. 2002). Recently, gene
polymorphisms of ACE and angiotensin type 1 receptors (AT1Rs) have been
positively associated with increased AAA incidence at 3 different geographic
areas (Fatini, Pratesi et al. 2005; Jones, Thompson et al. 2008). Moreover,
administration of an ACE inhibitor has been linked to reduced AAA ruptures in
human patients (Hackam, Thiruchelvam et al. 2006). Recent data demonstrated
that administration of an AT1R antagonist slowed AAA growth rate in a clinical
study involving a 25-years of AAA surveillance (Thompson, Cooper et al. 2010).
These data suggest that the RAS contributes to AAA progression; therefore,
inhibition of the RAS may slow AAA progression and potentially decrease the risk
of AAA rupture.
Our previous studies have demonstrated that with chronic AngII infusion
male mice exhibit a 4-5 fold higher prevalence of AAAs compared to female
mice, and this effect is abolished by orchiectomy (Daugherty, Manning et al.
2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). Exogenous
androgen administration restored AngII-induced AAA incidence in castrated male
mice and promoted aneurysm formation in female mice (Henriques, Zhang et al.
2008), suggesting androgen is a primary regulator of pronounced gender
differences in AngII-induced AAA formation. Relevance of these findings in mice
to humans is demonstrated by a strong effect of male gender as a risk factor for
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human AAA formation (ref). However, while male sex has been implicated as a
risk factor for AAA formation, results demonstrated that median growth rate of
AAAs was significantly greater in women than men (Mofidi et al., 2007). Thus, it
is unclear whether effects of androgen to promote formation of AngII-induced
AAAs extend to an increased progression of established AAAs.
To investigate if androgen also plays a role in AAA progression, we
hypothesized that castration reduces the growth rate of AngII-induced AAAs. We
performed orchiectomy to remove endogenous androgen from the male ApoE-/mice with established AngII-induced AAAs. Results from this study demonstrate
that castration significantly slows the progressive dilation of abdominal aortic
lumen in male ApoE-/- chronically infused with AngII.
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2.3 Methods
2.3.1 Animals
Male ApoE-/- mice were purchased from The Jackson Laboratory (2
months of age; n = 60; Bar Harbor, MA). All mice were maintained in a pathogenfree environment. Water and normal laboratory diet were available ad libitum. At
2 month of age, all mice were infused with AngII (1,000 ng/kg/min) for 4 weeks to
induce AAA formation. On day 25 of AngII infusion, abdominal aortas of all mice
were scanned by noninvasive high-frequency ultrasound to measure aortic lumen
diameter as an index of AAA formation. An AAA was defined as a >30% increase
in lumen diameter compared to baseline (day 0 of infusion). Only mice defined to
have an AAA continued in the study. These mice were assigned to either shamoperated or castration groups (n=23/group). Large and small AAAs, reflected by
abdominal aortic lumen diameters, were evenly assigned to both sham and
castration groups to control for differences in AAA size as a mediator contributing
to AAA progression. After surgery on day 28, mice in each group continued to be
infused with AngII for an additional 8 weeks. Abdominal aortic lumen diameters
were monitored by ultrasound on days 42, 56, 70 and 84.

2.3.2 AngII Infusion
Alzet (Durect Corp; Cupertino, CA) osmotic pumps (model 1004) were
filled with AngII (infusion rate of 1000 ng /kg/min) as described previously
(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000). Pumps were
implanted subcutaneously on the right flank via an incision in the scapular region.
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AngII infusions were continued each month by replacement of new osmotic
minipumps containing fresh AngII.

2.3.3 Orchiectomy
Male ApoE-/- mice were anesthetized with ketamine/xylazine (100/10
mg/kg, i.p.). Both testes were pushed down into the scrotal sacs by gently
applying pressure to the abdomen. An 8-10 mm incision through the skin was
made along the midline of the scrotal sac. Another incision was made into the
midline wall between the testes sacs under the covering membranes. The testis,
the vas deferens and epididymal fat pad were carefully pulled out through the
incision. The blood vessels supplying the testis were clamped with a hemostat
and the testis was dissected away. The vas deferens and the fat pad were
cauterized and placed back into the scrotal sac. This procedure was repeated for
the other testis. The incision through the skin was closed using wound clips. For
sham-operated controls, mice were anesthetized, both incisions were made and
sex organs were localized.

2.3.4 Ultrasound Imaging
Abdominal aortas of mice were visualized with high-frequency ultrasound
(Vevo 660, VisualSonics, Toronto, Canada) at baseline, days 25, 42, 56, 70 and
84 of AngII infusion, as previously described (Barisione, Charnigo et al. 2006).
Briefly,mice were anesthetized with isoflurane and restrained in a supine position
for ultrasonography. Short axis scans of aortas were performed on abdominal
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aortas from the level of the left renal arterial branch moving vertically to the
suprarenal region. Cine loops of 300 frames were acquired throughout the renal
region of abdominal aortas and maximal luminal diameters in the suprarenal
region of abdominal aortaswere measured on images at maximal dilation.

2.3.5 Atherosclerosis and AAA Quantification
Mice were sacrificed and fixed with formalin by gravity perfusion (~120
mmHg) to quickly preserve vessel morphology. Aortas were removed and fixed
with formalin overnight at room temperature. Extraneous tissue, including fat and
connective tissues were carefully removed from aortas. Atherosclerotic lesions
were quantified en face on the luminal surface of aortic arches as described
previously (Daugherty and Cassis 1999; Daugherty, Manning et al. 2000). Briefly,
atherosclerotic lesions were determined by measuring the area of the intimal
surface covered by grossly discernible atherosclerotic plaque, using ImagePro
Plus software (Media Cybernetics,Bethesda, MD). The extent of AngII-induced
atherosclerosis was expressed as the percentage of total lesion area to the total
aortic arch intimal area. Maximal diameters of suprarenal abdominal aortas were
measured on cleaned aortas by ImagePro Plus software (Media Cybernetics,
Bethesda, MD).

2.3.6 Statistical Analysis
Data are represented as mean ± SEM. To compare 2 groups, student’s t
test was performed for parametric data and Mann-Whitney Rank Sum Test was
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utilized for nonparametric data. Two-way repeated measures ANOVA with HolmSidak post hoc analysis were performed to compare body weight and ultrasound
data. The incidences of AAA were analyzed using Fisher exact test. P<0.05 was
considered statistically significant. All statistical analyses were performed using
SigmaStat (SPSS Inc).
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2.4

Results

2.4.1 Castration Reduces the Progressive Lumen Dilation of Established AngIIinduced AAAs in Male ApoE-/- Mice
To define the role of androgen on the expansion of established AngIIinduced AAAs, we infused adult male ApoE-/- mice with AngII for 4 weeks to
induce AAA formation before they were subjected to sham-operation or
orchiectomy. After surgery, we continued chronic AngII infusion in all mice for
another 2 months to study progression of established AAAs. After castration,
male mice exhibited significantly reduced body weights compared to sham
controls (Figure 2.1A). At the study endpoint, castrated male mice exhibited
marked atrophy in the weights of prostate, seminal vesicle and vas deferens
(Figure 2.1B).
At the end of 1 month of AngII infusion, we obtained abdominal aortic
lumen diameter measurements from AngII-infused AAAs by ultrasound.
Abdominal aortic lumen diameters at baseline and day 28 were not different
between sham controls and castrated mice (baseline, 1.07 ± 0.05 vs 1.05 ± 0.04
mm; day 28, 1.56 ± 0.05 vs 1.56 ± 0.04 mm; sham vs castration, respectively)
(Figure 2.2), demonstrating that AAAs of different sizes were evenly assigned to
sham control and castrated groups. In sham control mice, suprarenal aortic
lumen diameters progressively increased with continued infusion of AngII, with
significant increases in lumen diameter at days 70 and 84 of AngII infusion
compared to day 25 (day 25 vs day 70, 1.56 ± 0.05 vs 1.87 ± 0.05 mm; P<0.001)
(Figure 2.2). In contrast, aortic lumen diameters did not exhibit a progressive
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increase with continued AngII infusion in castrated male mice (day 25 vs day 70,
1.56 ± 0.04 vs 1.62 ± 0.04 mm; day 84, 1.56 ± 0.04 vs 1.63 ± 0.04 mm; P>0.23)
(Figure 2.2). As a result, aortic lumen diameters were reduced by castration on
days 56, 70 and 84 compared to sham operated controls (day 56, 1.74 ± 0.05 vs
1.50 ± 0.04 mm; day 70, 1.87 ± 0.05 vs 1.62 ± 0.04 mm; day 84, 1.88 ± 0.05 mm
vs 1.63 ± 0.04 mm; P<0.05; sham vs castration respectively) (Figure 2.2).

2.4.2 Castration Does not Alter Maximal External Diameters of AngII-induced
AAAs or AngII-induced Atherosclerosis.
During prolonged AngII infusion after the surgery, the castrated male mice
showed a tendency of decreased AAA rupture incidence compared with sham
controls (sham vs castration 13% vs 4%; P=0.60). At the study endpoint, aortas
were formalin fixed and cleaned for quantitative measurements of AngII-induced
AAA and atherosclerosis (Figure 2.4). Maximal external diameters of cleaned,
excised suprarenal aortas were reduced modestly (by 0.45 mm), but not
significantly by castration (sham vs castration, 2.32 ± 0.24 vs 1.87 ± 0.17 mm;
P=0.09) (Figure 2.3A). AngII-induced atherosclerosis in aortic arches was not
different between sham and castrated mice (sham vs castration, 6.2 ± 0.5 vs 6.6
± 0.7 %; P=0.27) (Figure 2.3B).
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2.5

Discussion
The major finding of this study is that castration substantially reduces

luminal dilation of established AngII-induced AAAs in male ApoE-/- mice. Our
data support that prolonged AngII infusion causes progressive elevations in
suprarenal aortic lumen diameters of male ApoE-/- mice, consistent with previous
studies (Barisione, Charnigo et al. 2006). Interestingly, despite an ability of
castration to significantly blunt progressive dilation of suprarenal aortic lumen
diameters with prolonged AngII infusion, castration only modestly reduced AAA
external diameters. These data suggest that inhibition of androgen suppresses
AAA progression.
In contrast to an ability of castration to blunt progressive increases in
aortic lumen diameters, castration of male mice had no effect on atherosclerotic
lesions formed from chronic AngII infusion. These results are in agreement with
previous data from our laboratory demonstrating that sex differences in AngIIinduced vascular diseases are restricted to AAAs (Henriques et al., 2004).
Although male gender is linked to higher risks of cardiovascular diseases
including AAAs, low serum testosterone in men has also been associated with
increased cardiovascular risk and mortality (Shores, Matsumoto et al. 2006;
Maggio, Lauretani et al. 2007; Laughlin, Barrett-Connor et al. 2008). Recently it
has been demonstrated that androgen deprivation therapy for prostate cancer
increased the risk of cardiovascular events (Levine, D'Amico et al.). Moreover,
women often have more adverse outcomes after a cardiovascular event
compared to men of a similar age (Kostis, Wilson et al. 1994; Vaccarino, Parsons
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et al. 1999; Vaccarino, Parsons et al. 2009). It has been suggested that
androgen plays an important role in cardiovascular repair and regeneration
through stimulating erythropoietin production and angiogenesis via VEGF-related
mechanisms (Sieveking, Chow et al.). Recent animal studies also revealed that
androgen is required for the preservation of NO bioavailability and exerts
protective effects against AngII-induced vascular remodeling in coronary arteries
and thoracic aortas from male mice by regulating oxidative stress (Ikeda, Aihara
et al. 2009). Our results do not support a protective role for testosterone in the
progression of AngII-induced atherosclerosis. It is possible that augmentation of
atherosclerosis by chronic infusion of AngII occurs through mechanisms that are
independent of those suggested to be favorably influenced by testosterone.
In contrast to a lack of effect on atherosclerosis, castration totally ablated
progressive increases in suprarenal aortic lumen diameters of AngII-infused male
mice. Male gender has been identified as a prominent risk factor of human AAA
formation by numerous epidemiological and clinical studies. However, whether
male gender influences the growth rate of formed AAA remains largely under
debate. Results from the United Kingdom Small Aneurysm Trial demonstrated no
association of gender with AAA growth (Brady, Thompson et al. 2004).
Interestingly, despite a higher AAA incidence in males compared to females,
some studies have noted increased AAA expansion rate and aneurysmal
ruptures in female AAA patients (Solberg, Singh et al. 2005; Mofidi, Goldie et al.
2007; Norman and Powell 2007). In contrast, female gender also has been
negatively associated with AAA progression (Thompson, Cooper et al.). A
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interesting recent study genotyped 74 single-nucleotide polymorphisms (SNPs)
in genes determining circulating sex hormones and their action in males with and
without AAAs, and demonstrated that one SNP in CYP19A1 was strongly
associated with aortic diameter (Golledge, Biros et al. 2010). However, similar
studies have not been performed in females. To our knowledge, no studies have
examined the association of AAA progression and male/female gender in AAA
animal models.
In agreement with human AAAs, we have previously demonstrated that
castration strikingly reduces AngII-induced AAA incidence in male mice while
exogenous androgen administration restored AAA formation in castrated males,
indicating an important role of androgen in the formation of AngII-induced AAAs
(Henriques, Huang et al. 2004; Henriques, Zhang et al. 2008). In this study, we
demonstrate that castration significantly reduced the progressive lumen dilation
of established AngII-induced AAAs, suggesting that androgen also plays a role in
luminal expansion of AAAs in male mice. While castration is not an amenable
therapy to treat AAAs in humans, these results suggest that androgen receptor
blockade may be of benefit in advancing AAAs, or alternatively that use of
anabolic steroids may be contraindicated in males of advancing age with a family
history of AAAs.
Despite the ability of castration to significantly reduce aortic lumen dilation
of progressing AAAs, external AAA diameters were modestly, but not significantly
decreased by castration. External diameters of cleaned AAAs encompass lumen
diameters and abdominal aortic vascular wall remodeling. A reduction in lumen
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diameter in the face of a modest but yet insignificant decrease in external
diameter suggests that aortic wall remodeling was not appreciably reduced by
castration with prolonged AngII infusion. Recent studies demonstrated that
testosterone inhibits vascular calcification (Son, Akishita et al. 2010), suggesting
that continued aortic remodeling in castrated male mice may have resulted from
removal of the inhibitory effects of castration on vascular calcification. It is
unclear whether changes in lumen diameter, as compared to aortic wall
diameter, are more closely linked to rupture of AAAs. This is especially difficult
to ascertain as ultrasound can be used to accurately quantify aortic lumen, but
not aortic wall diameters in mice, while in humans ultrasound assesses aortic
diameters (lumen plus wall). Our results demonstrate a modest reduction in
aneurismal rupture in castrated male mice compared to sham controls,
suggesting that castration-induced decreases in aortic lumen diameter are more
closely linked to rupture of AngII-induced AAAs.
In conclusion, castration significantly decreased the progressive lumen
dilation of established AngII-induced AAAs in male ApoE-/- mice, but had no
effect on external AAA diameters. These studies suggest that androgen
contributes to the progression of established AAAs through distinct mechanisms
that differentially influence aortic lumen and wall diameters.

Copyright © Xuan Zhang 2011
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Figure 2.1 Body weights through AngII infusion (A) and male sex organ tissue
weights at study endpoint (B) of both sham and castration group. Data are mean
± SEM. *, P < 0.001 compared to day 28 within each group; **, P < 0.001
compared to control group.
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Figure 2.2 Lumen diameters of suprarenal abdominal aortas were obtained from
sham and castration groups using ultrasound through 3 months AngII infusion.
Data are mean ± SEM. *, P < 0.001 compared to day 28 measurements within
each group; **, P < 0.05 compared to control group.
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Figure 2.3 Castration does not significantly reduce maximal external diameters of
AngII-induced AAA (A; P=0.09) or have any impact on AngII-induced
atherosclerosis in aortic arch (B; NS). Each circle represents the measurement
from each individual sample.
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Figure 2.4 Perfusion fixed aortas from sham and castration groups.
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CHAPTER III. SPECIFIC AIM 2

Determine the effect of androgen on aortic angiotensin receptor type 1a
expression and the effect of smooth muscle angiotensin receptor type 1a
deficiency on angiotensin II-induced AAA formation in female hyperlipidemic
mice administered exogenous androgen.

3.1

Summary
Our previous studies have demonstrated that AngII infusion induce AAA

formation through AT1aR. Castration of male ApoE-/- reduces AngII-induced
AAA to that of female mice while androgen administration restores or stimulates
AAA formation in castrated male mice or female mice. Thus, we sought to
determine if androgen positively regulate aortic AT1aR expression to confer a
higher AngII-induced AAA incidence and if SMC AT1aR deficiency reduce the
effect of androgen on increasing AAA formation in female mice.
AT1aR mRNA abundance in the AAA-prone region of abdominal aortas
was 7-fold greater compared to thoracic aortas of male but not female mice.
AT1aR mRNA abundance decreased after castration in abdominal but not
thoracic aortas of male mice. Exogenous androgen (dihydrotestosterone, DHT)
administration to castrated male mice restored AT1aR mRNA abundance in
abdominal aortas but had no effect in thoracic aortas. DHT also stimulated
AT1aR mRNA abundance in abdominal aortas from female mice. When treated
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with testosterone, primary cultured smooth muscle cells exhibited significant
increase of AT1aR mRNA abundance.
To investigate if exogenous androgen stimulates AT1aR expression on
SMC to promote AngII-induced AAA in female mice, SMC specific AT1aR
deficient mice were generated using Cre-LoxP technology. Both AT1aR deficient
mice and wild type littermate control female mice were administered DHT for 2
week before infused with AngII. AngII-induced AAA incidence was significantly
reduced with SMC AT1aR deficiency (85% vs 50%; P<0.05).
In conclusion, these studies demonstrate that enhanced abdominal aortic
AT1aR level by androgen is highly correlated with increased AngII-induced AAA
formation in adult mice. Furthermore, exogenous androgen positively regulates
SMC AT1aR expression to promote AngII-induced AAA susceptibility in adult
female hyperlipidemic mice.
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3.2

Introduction
Male gender has been consistently identified as a major risk factor for

human AAAs. The incidence and severity of abdominal aortic dilations are
greater in men than women (Singh, Bonaa et al. 2001; Isselbacher 2005).
Experimental models of this disease also exhibit similar gender differences. In
the rat model of intraluminal elastase infusion induced AAAs, male rats had
larger and more frequent aneurysms than females (Ailawadi, Eliason et al. 2004).
Chronic AngII infusion into hyperlipidemic mice resulted in AAA formation at a 45 fold higher incidence in male compared to female mice (Daugherty, Manning et
al. 2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004). It has
been demonstrated that removal of androgen by castration of male ApoE-/- mice
profoundly reduced AngII-induced AAA incidence to a similar level of female
ApoE-/- mice while ovariectomy had no significant influence on AngII-induced
AAA formation in female ApoE-/- mice (Henriques, Huang et al. 2004). Recent
studies also demonstrated that exogenous androgen administration restores
AngII-induced AAA formation in castrated male ApoE-/- mice and significantly
augments AAA incidence in female ApoE-/- mice (Henriques, Zhang et al. 2008).
These data implicate androgen as a primary mediator of gender differences in
AngII-induced AAAs; however, mechanisms of androgen to promote AAA
formation are unknown.
Androgen has been reported to increase the expression of each
component of the renin-angiotensin system (RAS), including angiotensinogen,
renin, ACE and AT1 receptors (Fischer, Baessler et al. 2002). Previous studies in
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our laboratory demonstrated that both the AT1 receptor antagonist losartan
administration and AT1aR deficiency abolishes AngII-induced AAAs in male
mice, implicating a pivotal role of AT1aR in AngII-induced AAA formation
(Daugherty, Manning et al. 2001; Cassis, Rateri et al. 2007). Moreover, using
bone marrow transplantation, AT1aR deficiency of recipient mice, but not in cells
used to repopulate, reduced AngII-induced AAAs (Cassis, Rateri et al. 2007). In
aortic vasculature, several cell types express AT1aRs. The expression level of
AT1aR is highest in SMC of vessel wall (Mehta and Griendling 2007). SMC
apoptosis has been found to contribute to AngII-induced AAAs, since
administration of a caspase inhibitor reduced medial apoptosis and significantly
decreased AAA formation (Yamanouchi, Morgan et al. 2010). Previous studies
examining temporal changes in aneurismal pathology with AngII infusion
demonstrated medial smooth muscle elastin degradation occurred early in AngIIinduced AAAs (Saraff, Babamusta et al. 2003). Collectively, these results
demonstrate that AngII induces AAA formation through stimulation of AT1aRs,
and support an essential role on vascular SMC in AAA formation.
In this study, we tested the hypothesis that androgen increases AT1aR
expression on aortic SMC to promote AngII-induced AAAs in female
hyperlipidemic mice. We first examined the effect of exogenous androgen on
AT1aR mRNA abundance in thoracic versus abdominal aortas from castrated
male and female ApoE-/- mice. Then, we defined the role of AT1aR on aortic
SMC in the effect of exogenous androgen to augment AngII-induced AAA
formation in female mice.
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3.3

Methods

3.3.1 Animals
For studies examining the effects of androgen on AT1aR mRNA
abundance, Male and female apoE-/- mice (12 weeks old, backcrossed 10 times
onto aC57BL/6 background) were purchased from Taconic Farms (Germantown,
PA). All mice were maintained under barrier conditions. Water and normal
laboratory diet were available ad libitum. Male and female mice were castrated
as described previously and 1 week later implanted in the subcutaneous space
with slow release pellets (Innovative Research of America, Sarasota, FL)
containing vehicle or dihydrotestosterone (DHT; 10 mg pellets/60 day sustained
release; 0.16 mg/d). Castrated male mice administered vehicle or DHT were
examined at 1 or 5 weeks after DHT administration (n=10 to 13 per treatment per
time point). A group of ovariectomized female apoE-/- mice were included, with
vehicle or DHT (0.16 mg/d) administration beginning 1 week after castration for a
total duration of 5 weeks (n=8 per treatment group).
For the study determining the role of SMC AT1aR on androgen increasing
AngII-induced AAA susceptibility in female mice, 3 month old female AT1aRfl/fl
and AT1aRSM22 KO mice were implanted AT1aRSM22 KO micedihydrotestosterone
(DHT; 10 mg pellets/60 day sustained release; 0.16 mg/day) 2 weeks before
infused with AngII (1,000ng/kg/min, Bachem, Torrance, CA) by osmotic pumps
(Alzet, model 1004, Durect Co., Cupertino, CA) for 4 weeks.
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3.3.2 Orchiectomy and Ovariectomy
Ovariectomy was performed on 3-month-old female apoE-/- mice. Mice
were anesthetized with ketamine/xylazine, bilateral incisions (approximate 0.5 cm
in length) were made into the abdominal cavity, and the uterus was exposed. The
ovaries were carefully picked out of the incisions. Circulation to the fallopian
tubes was cut off with a hemostat to minimize bleeding when dissecting the
ovaries. Once the ovaries were excised, the cut end of the fallopian tubes was
cauterized and all the tissues were neatly placed back into the abdominal cavity.
The muscle was then sutured, and the skin was closed using wound clips. Sham
controls were subject to a similar procedure without removing the ovaries.
Orchiectomy surgeries were performed on 3-month-old male apoE-/- mice as
previously described.

3.3.3 Generation of AT1aRSM22 KO mice
AT1aRfl/fl were generated by InGenious Targeting Laboratory (Stony Brook,
NY) directly in ES cells of C57BL/6 mice and subsequently crossed to LDLR-/mice. SM22-Cre mice (The Jackson Laboratory, Tg(Tagln-cre)1Her/J, #004746,
Bar Harbor, ME) were bred to LDLR-/- mice and were identified by speed
congenic screening (The Jackson Laboratory) to be the equivalent of N10. For
experimental mice, male AT1aRSM22 KO mice were bred to female AT1aRfl/fl mice
to generate approximately 50:50 distribution of Cre hemizygous transgenics
(AT1aRSM22 KO) and non Cre expressing littermate controls (AT1aRfl/fl).
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3.3.4 Genotyping
AT1aRSM22 KO and AT1aRfl/fl littermate controls were genotyped by PCR
of genomic DNA (tail) and smooth muscle AT1aR deficiency confirmed using
aortic samples at study endpoint. A small piece of infrarenal aorta was removed,
cleaned of adventitia and endothelium and DNA was extracted (DNeasy; Qiagen,
Alameda, CA). The primers and PCR conditions used for genotyping are listed in
Table 3.1.

3.3.5 Aortic gene expression quantification by real time PCR
Total RNA was extracted from thoracic (aortic arch to diaphragm) and
abdominal aortas (diaphragm to ileal bifurcation) using RNeasy fibrous tissue
minikit (Qiagen, Valencia, CA). For in vitro experiments, primary mouse vascular
smooth cells (passage 7-10) were treated with 10nM of testosterone propionate
(Sigma Aldrich, St. Louis, MO) in 0.1% DMSO for 24 hours. Total RNA was
extracted with Trizol (Invitrogen, Carlsbad, CA). All RNA samples were treated
with Turbo DNA-free (Ambion, Austin, TX) to remove genomic DNA.RNA quality
was assessed using a Bio-Rad Experion Automated Electrophoresis System
(Bio-Rad, Hercules, CA). Mouse AT1aR primers were obtained from Qiagen,
while AT1bR primers were from Applied Biosystems TaqMan Gene Expression
Assays. Relative quantification of AT1aR mRNA abundance was performed with
an iCycler (BioRad, CA) based on a standard curve method using the SYBR
Green PCR core reagent (Applied Biosystems, CA). The real-time PCR
conditions were: 5 min at 94º, 40 cycles for 1 min at 94º, 1 min at the annealing
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temperature, 1 min at 72º, and a final elongation step for 10 min at 72º. To verify
specificity of primers for AT1aR, quantification was performed on tissues from
AT1aR-/- mice. 18S rRNA was used to control for DNA loading, and data are
expressed as AT1aR/18S RNA ratios.

3.3.6 Measurement of aortic contractility
Aortas from intact male, castrated male, and castrated male ApoE-/- mice
administered DHT (5 weeks) were removed and adventitia was carefully
dissected free. Measurement of contractile activity was performed using ring
segments (3 mm) from thoracic and abdominal aortas as described previously
(Babamusta, Rateri et al. 2006). Aortic segments were mounted by passing two
tungsten wires through the arterial lumen and bathed in wells filled with Krebs
Henseleit solution. Optimal resting tension (1 gm) was maintained continuously
and recorded on a Micro-Med instrument. After 30 min for equilibration, tissues
were incubated with KCl (60 mM), followed by AngII (1 µM). The contractile force
generated in response to AngII was normalized as a percentage of the KCl
response.

3.3.7 Quantification of atherosclerosis and AAAs
Atherosclerotic lesions were quantified in the aortic arch as described
previously (Daugherty, Manning et al. 2000; Daugherty and Whitman 2003). AAA
incidence was quantified by grading of excised, cleaned tissue by 3 independent
observers blinded to the experimental design as described previously. Abdominal
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aortic lumen diameter measurements were obtained on anesthetized mice using
high-resolution ultrasound (Visualsonics, Vevo 660) at baseline, day 7, day 14
and day 28 of AngII infusion. Maximal diameters of abdominal aortas were
measured on cleaned, formalin-fixed aortas by ImagePro Plus software (Media
Cybernetics, Bethesda, MD). AAAs were defined as > 50% dilation of lumen
diameters from saline-infused mice.

3.3.8 Statistical Analyses
Data are represented as mean±SEM. Parametric data were initially
analyzed using ANOVA. If differences existed between groups, post hoc
analyses were performed (Tukey). The incidences of AAA were analyzed using
Fisher exact test. P=0.05 was considered statistically significant. All statistical
analyses were performed using SigmaStat (SPSS Inc).
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3.4

Results

3.4.1 Androgen Selectively Augments Abdominal Aortic AT1aR Expression in
Both Male and Female ApoE-/- mice
To determine if aortic AT1aR was regulated by androgen to promote
AngII-induced AAA formation, male and female ApoE-/- mice were subjected to
orchiectomy or ovariectomy operation and administerd exogenous androgen,
DHT for 1 or 5 weeks. Abdominal aortas, where AngII-induced AAAs form in
mice, exhibit strikingly higher (7-fold) AT1aR mRNA abundance than thoracic
aortas in male but not female ApoE-/- mice (Figure 3.2). AT1aR mRNA
abundance progressively decreased after castration in abdominal aortas to levels
observed in thoracic aortas. Administration of DHT for 1 week to castrated male
apoE-/- mice resulted in complete restoration of AT1aR mRNA abundance in
abdominal aortas, but had no effect in thoracic aortas (Figure 3.2A). Longer
exposures to DHT (5 weeks) also increased AT1aR mRNA abundance in
abdominal aortas to levels not different from intact male mice (Figure 3.2A).
Interestingly, administration of DHT (total of 5 weeks) to ovariectomized female
apoE-/- mice also resulted in increased AT1aR mRNA abundance in abdominal
but not thoracic aortas (Figure 3.2B).

3.4.2. Androgen Fails to Regulate Aortic AT1bR Expression in ApoE-/- Mice
To determine whether androgen regulation of AT1 receptors was
restricted to the AT1aR subtype, we examined AT1b mRNA abundance in
thoracic and abdominal aortas from male and female mice in each group. AT1bR

86

mRNA abundance was greater in abdominal compared to thoracic aortas from
male and female ApoE-/- mice, with similar expression levels in aortas from male
and female mice (Figure 3.3). In addition, AT1bR mRNA abundance in
abdominal aortas was not altered by castration or by DHT administration to
castrated male or female ApoE-/- mice (Figure 3.3). Despite the presence of
both AT1aR and AT1bR in aortas, aortic AT1bR has been demonstrated to be
primarily responsible for AngII-mediated contractile responses of abdominal
aortas (Zhou, Dirksen et al. 2005; Swafford, Harrison-Bernard et al. 2007). We
defined the contractile response to Ang II in aortic rings from thoracic versus
abdominal aortas of male and female ApoE-/- mice. In agreement to previous
findings (Zhou, Dirksen et al. 2003), The contractile response to Ang II was
greater in abdominal than thoracic aortas from male and female ApoE-/- mice
and was of similar magnitude in aortas from male and female mice (Figure 3.4).
Moreover, there was no difference in Ang II–induced contractile responses in
castrated (5 weeks) male or female mice or in mice administered DHT (5 weeks)
(Figure 3.4).

3.4.3. Androgen enhances SMC AT1aR Expression to promote AngII-induced
AAAs in Female Hyperlipidemic Mice
We examined effects of testosterone on AT1aR mRNA abundance using
primary cultures of mouse aortic smooth muscle cells. Incubation of mouse
aortic smooth muscle cells with testosterone significantly increased AT1aR
mRNA abundance, implicating smooth muscle cells as targets of androgen to
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increase aortic AT1aR mRNA abundance (Figure 3.6). Previous studies
demonstrated that administration of DHT to adult female ApoE-/- mice increased
AngII-induced AAAs, but had no effect on atherosclerosis (Henriques, Zhang et
al. 2008). Therefore, we first investigated the role of SMC AT1aR in DHTmediated promotion of AngII-induced AAAs and atherosclerosis in adult female
LDLR-/- mice.
We used Cre-LoxP technology to generate mice with deficiency of AT1aR
in smooth muscle cells. Mice were engineered with loxP sites flanking exon 3 of
AT1aR which includes the entire coding region for the receptor protein (Figure
3.7A). AT1aRfl/fl females on an LDLR-/- background were mated to male mice
expressing Cre recombinase under the control of an SM22 promoter to generate
smooth muscle AT1aR deficient mice (Kuhbandner, Brummer et al. 2000;
Holtwick, Gotthardt et al. 2002) and littermate controls (AT1aRfl/fl). Depletion of
AT1aR exon 3 from smooth muscle cells was verified by PCR of genomic DNA
from aortas (Figure 3.7B). Female AT1aRfl/fl and AT1aRSM22 KO mice were
administered DHT at 2 months of age beginning 2 weeks before AngII infusion.
Consistent with previous findings (Henriques, Zhang et al. 2008), administration
of DHT to adult AT1aRfl/fl female mice resulted in robust AngII-induced AAAs
(Figure 3.7A; AAA incidence, 87%). In contrast, AT1aRSM22 KO females
exhibited significantly reduced AAA formation (AAA incidence, 50%; P<0.05),
abdominal aortic lumen diameters (Figure 3.8A) and maximal aortic diameters of
suprarenal aortas (1.90 ± 0.22 vs. 1.35 ± 0.14 mm; P<0.05) (Figure 3.8B). In
addition, aneurismal rupture in adult DHT-treated females was decreased by
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AT1aRSM22 KO (WT, 40%; SMC AT1aR KO, 13%; Figure 3.7B). In contrast,
smooth muscle AT1aR deficiency had no effect on aortic arch atherosclerotic
lesion sizes or ascending aortic dilation in DHT-treated females (Figure 3.9).
These results indicate an important role for smooth muscle AT1aR in androgenmediated promotion of AngII-induced AAAs in adult female mice.
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3.5

Discussion
Results from this study demonstrate that male, but not female ApoE-/-

mice, exhibit regional differences in AT1aR mRNA abundance in aortas, with
greater receptor expression in abdominal compared to thoracic aortas.
Moreover, castration of male ApoE mice resulted in a specific reduction in AT1aR
mRNA abundance in abdominal aortas, which was restored by DHT
administration. Interestingly, DHT also increased AT1aR mRNA abundance in
abdominal aortas from female ApoE-/- mice. These effects of androgen to
promote AT1aR mRNA abundance specifically in abdominal aortas were
associated with increased AAA incidence and severity in both male and female
castrated ApoE-/- mice.
The effect of androgen on AT1 receptor expression has been relatively
unexplored. In rat epididymis, castration reduced AT1 receptor protein, that was
restored when rats were treated with testosterone (Leung, Wong et al. 2002).
Moreover, androgen was reported to increase AngII receptors in bovine adrenal
glomerulosa cells (Carroll and Goodfriend 1984). In contrast neither castration
alone or combined with androgen administration regulated AT1 receptor mRNA
abundance in homogenates of renal cortex punches from male New Zealand
genetically hypertensive rats (Song, Kost et al. 2006). In addition, incubation of
androgen-dependent human prostate cancer cells with DHT increased AT1
receptor mRNA and protein (Uemura, Hasumi et al. 2006), supporting androgen
regulation of human AT1 receptors. Our results demonstrate a specific effect of
androgen to regulate AT1aR mRNA abundance in abdominal, but not thoracic

90

aortas. Taken together, these results suggest that androgen exhibits tissue
and/or cell-specific regulation of AT1 receptors. Interestingly, recent studies
demonstrated that smooth muscle cells of the ascending and arch portions of the
aorta are derived from murine neural crest, while smooth muscle cells of the
abdominal aorta are derived predominately from mesenchymal cells in
splanchnic mesoderm (Majesky 2007). It has been demonstrated that these
mesenchymal cells during development exhibits androgen receptor (AR) activity
(Cunha, Shannon et al. 1981; Majesky 2007; Wasteson, Johansson et al. 2008).
Interestingly, we also demonstrate that AR mRNA abundance is greater in
abdominal aortas compared to in thoracic aortas in both male and female ApoE/- mice (Figure 3.5). This specific regional expression pattern of AR correlates
with highly selective upregulation of abdominal aortic AT1aR by androgen in
adult ApoE-/- mice. Overall, these results suggest that the differences in smooth
muscle embryonic origins along the length of the aorta may have contributed to
regional differences in AT1aR regulation by androgen.
Previous investigators have demonstrated greater AngII-induced
contractile responses in abdominal compared to thoracic aortic ring segments
from male C57BL/6 mice (Zhou, Dirksen et al. 2003). Further studies
demonstrated a prominent role for AT1b receptors in AngII-induced contractile
responses (Zhou, Chen et al. 2003; Swafford, Harrison-Bernard et al. 2007). Our
results extend these findings by demonstrating greater AT1aR mRNA abundance
in abdominal aortas from male, but not female mice. To define whether androgen
effects were restricted to the AT1aR subtype, we measured AT1bR mRNA
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abundance, and the contractile response to AngII as an index of AT1b receptor
function. While the contractile response to AngII exhibited a similar regional
specificity to the abdominal aorta of male and female ApoE-/- mice, AngIIinduced contraction was not regulated by androgen, nor was AT1bR mRNA
abundance. These results demonstrate that androgen specifically regulates
aortic AT1a receptors. Given that AT1a and AT1b receptor subtypes exhibit
differential cell and tissue distribution, differences in the promoters of these
distinct genes may contribute to androgen-specific effects to increase AT1aR
mRNA abundance.
Vascular SMC plays an essential role in AAA pathogenesis. Previous
results implicated medial elastin degradation as an early event in AAA formation
in adult male ApoE-/- mice (Saraff, Babamusta et al. 2003). Apoptosis of smooth
muscle has been found to contribute to AngII-induced AAAs, since administration
of a caspase inhibitor reduced medial apoptosis and significantly decreased AAA
formation (Yamanouchi, Morgan et al.). Moreover, genetic deficiency of
cyclophilin A, a chaperone protein abundantly expressed in smooth muscle cells,
abolished AngII-induced AAAs (Satoh, Nigro et al. 2009). Our results
demonstrate that testosterone increases AT1aR mRNA expression in primary
cultured mouse aortic smooth muscle cells. Moreover, deficiency of AT1aR in
smooth muscle decreased effects of exogenous androgen to promote AngIIinduced AAAs in adult female mice, but had no effect on atherosclerosis or
ascending aortic dilation induced by infusion of AngII. Interestingly, in this study,
AAAs that did form in female mice with smooth muscle cell AT1aR deficiency had
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similar pathologic characteristics to those of wild type controls. Thus, as
opposed to downstream signaling pathways, androgen may influence initiating
events in the formation of AngII-induced AAAs by promoting AT1aR expression
in pivotal cell types, including vascular smooth muscle cells. In conclusion, these
data suggest that promotion of these AngII/AT1aR-mediated effects in smooth
muscle cells contribute to enhanced AAA formation in adult female mice exposed
to exogenous androgen.

Copyright © Xuan Zhang 2011
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Table 3.1 PCR primers and conditions used for AT1aRfl/fl and AT1aRSM22 KO
mice genotyping.
Gene

Product PCR anealing
Primers

screened
Cre

size

temperature

182 bp

57.5ºC

324 bp

57.5ºC

262 bp

53ºC

531 bp

53ºC

5'-CTAGGCCACAGAATTGAAAGATCT

transgene 5'-AGTAGGTGGAAATTCTAGCATCATCC
5'-ACCTGAAGATGTTCGCGATT
IL-2
5'-CGGCATCAACGTTTTCTTTT
Floxed

5'-TGTTGCATCTACATCCTG

AT1aR

5'-TCTAAAGAAACCTCATGAAC

Excised

5'-TGTTGCATCTACATCCTG

AT1aR

5'-TGTTTGGGGGTTTTTGTTGT
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Group

Gender

Number

Surgery

Treatment

1

Male

13

No

No

2

Male

9

1 week placebo

3

Male

10

1 week DHT

4

Male

12

5 week placebo

5

Male

12

5 week DHT

6

Female

7

5 week placebo

7

Female

8

Orchiectomy

Ovariectomy
5 week DHT

Figure 3.1 Schematic representations of the experimental groups and study
design as described in the methods section.
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Figure 3.2 DHT augments AT1aR mRNA abundance in abdominal aortas from
male and female ApoE-/- mice. A, In males, AT1aR mRNA abundance was
greater in abdominal than thoracic aortas. Castration decreased, whereas DHT
restored AT1aR mRNA abundance in abdominal aortas. B, In females, DHT
increased AT1aR mRNA abundance in abdominal aortas. Data are mean ± SEM.
* P<0.05 compared to thoracic; **P<0.01compared to intact.
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Figure 3.3 AT1bR mRNA abundance in abdominal and thoracic aortas from male
(A) and female (B) ApoE-/- mice was not altered by castration (1 or 5 weeks), or
by DHT administration (1 or 5 weeks). However, AT1bR mRNA abundance was
greater in abdominal compared to thoracic aortas from male and female mice,
and was similarly expressed in aortic regions from male compared to female
mice. * P<0.01 compared to thoracic aortas within treatment group.
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Figure 3.4 Contractile responses of aortic (thoracic and abdominal) rings to AngII
(1 μM, as a % of the KCl response) in male (A) and female (B) mice was not
altered by castration, or by DHT administration. However, AngII-induced
contraction was greater in abdominal compared to thoracic aortas, and was
similar between male and female ApoE-/- mice. * P<0.01 compared to thoracic
aortas within treatment group.
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Figure 3.5 Androgen receptor (AR) mRNA abundance was greater in abdominal
compared to thoracic aortas both male (A) and female (B) ApoE-/- mice. * P<0.01
compared to thoracic aortas within treatment group. **P<0.05 compared to
ovariectomy.
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0.005

*

AT1aR/18s ratio

0.004

0.003

0.002

0.001

0.000
vehicle

testosterone

Figure 3.6 AT1aR mRNA abundance in mouse aortic smooth muscle cells was
increased by testosterone (10 nM; 24 hours of incubation). All results represent
3 replicates with each treatment performed in triplicate. *, P < 0.05 compared to
DMSO vehicle control.
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A

E1

E2

E3

Wildtype allele
E1

E2

E3
neo

E1

Floxed allele

E2

Cre mediated excision

B

Cre 0/0

Cre 1/0

Cre 0/0

Cre 1/0

AT1aRSM22 KO

IL-2
Cre

AT1aRfl/fl

Figure 3.7 Generation (A) and DNA genotyping (B) of smooth muscle AT1aR
deficient LDLR-/- mice. (A) Gene map of partial AT1aR gene locus, floxed AT1aR
allele and SM22-Cre driven deletion allele. (B) PCR reactions were performed
with DNA samples extracted from aortic smooth muscle cells. Left, PCR for IL-2
was used to control for DNA loading, and primers for Cre were used to identify
Cre1/0 mice. Right, in mice expressing the Cre transgene (Cre 1/0), exon 3 of
AT1aR was deleted as demonstrated by the presence of a 531bp DNA product
(AT1aRSM22 KO) and the disappearance of 262bp DNA product (AT1aRfl/fl).
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Figure 3.8 SMC AT1aR deficiency reduces AAAs in adult female mice
administered DHT and infused with AngII. (A) AAA incidence in AT1aRfl/fl or
AT1aRSM22 KO female mice. (B) Survival curves for AT1aRfl/fl or AT1aRSM22 KO
female mice. *, P<0.05 compared to AT1aRfl/fl .
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A

AT1aRfl/fl

2.5

Abdominal aortic
lumen diameter (mm)

AT1aRSM 22KO
2.0

*

1.5

*

1.0

*

0.5
0

7

14

28

Time (days)

B

Maximal external
abdominal diameter (mm)

3.5
3.0
2.5
2.0

*

1.5
1.0
0.5
0.0
AT1aRfl/fl

AT1aRSM22KO

Figure 3.9 SMC AT1aR deficiency decreases abdominal aortic lumen diameters
(A) and maximal external abdominal diameters (B) in adult female mice
administered DHT and infused with AngII. Triangles are individual mice with
circles representing mean ± SEM. *, P<0.05 compared to AT1aRfl/fl .
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A
35
30

% lesion

25
20
15
10
5
0

B

AT1aRfl/fl

AT1aRSM22KO

AT1aRfl/fl

AT1aRSM22KO

30

Arch area (mm2)

28
26
24
22
20
18
16
14

Figure 3.10 SMC AT1aR deficiency has no effect on AngII-induced
atherosclerosis in aortic arch or ascending aortic dilation. (A) Atherosclerotic
lesion sizes in aortic arch of mice from each genotype. (B) Aortic arch areas,
dictating ascending aortic dilation, from each genotype. Triangles are individual
mice with circles representing mean ± SEM.
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CHAPTER IV. SPECIFIC AIM 3

Determine the effect of androgen administration in neonatal female mice
on aortic smooth muscle angiotensin receptor type 1a expression and
angiotensin II-induced AAA formation in adulthood.

4.1

Summary
Our previous studies have demonstrated that androgen promotes AAA

pathology in adult males through upregulation of AT1aR in abdominal aortas.
Mechanisms for regulation of AT1aR in abdominal aortas by testosterone are
unclear, but may relate to developmental effects on vascular wall cells. Thus, we
sought to determine if administration of testosterone to neonatal female
apolipoprotein E (ApoE) -/- or LDL receptor (LDLR)-/- mice confers adult
susceptibility to AngII-induced AAAs.
One day old female mice were administered testosterone and AngIIinduced vascular diseases were defined in adult females. Neonatal exposure to
testosterone increased aortic AT1aR expression and promoted a striking
increase in AngII-induced atherosclerosis, ascending aortic aneurysm and AAA
(20% vs 64%; P<0.05) in adult female hyperlipidemic mice. These effects were
independent of a requirement for circulating testosterone. Deficiency of AT1aR
in smooth muscle cells reduced effects of neonatal or adult testosterone to
promote AAAs in adult females, but did not alter atherosclerosis or aortic arch
aneurysms. These data define a previously unrecognized role of sex hormone
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exposures during development to confer enhanced susceptibility to distinct
vascular diseases.
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4.2

Introduction
Pioneering studies by Barker et al initiated the concept that exposure to

environmental stimuli, including sex hormones, during critical periods of
development influence disease susceptibility in adult life. It is well established
that several types of cardiovascular diseases exhibit sex differences, typically
with enhanced disease development in males compared to females. Sex
hormone influences have been demonstrated to contribute to sex differences
between adult males and females, most commonly studied in the context of loss
of female sex hormones during menopause as a contributor to higher
cardiovascular disease development in aging females. By comparison,
influences of sex hormone exposure during development on cardiovascular
disease susceptibility in later life remains poorly defined.
Previous studies in our laboratories demonstrated that chronic AngII
infusion in hypercholesterolemic male mice increases atherosclerosis and
induces formation of aneurysms in the ascending and suprarenal aorta
(Daugherty and Cassis 1999; Daugherty, Manning et al. 2000; Daugherty, Rateri
et al. 2010). These AngII-induced vascular pathologies are mediated through
angiotensin type 1a receptors (AT1aR) (Daugherty, Rateri et al. 2004; Cassis,
Rateri et al. 2007). Interestingly, despite being induced by infusion of the same
peptide, only AAAs exhibit marked sex differences with higher prevalence (4-fold)
in male compared to female mice (Daugherty and Cassis 1999; Daugherty,
Manning et al. 2000; Manning, Cassis et al. 2002; Henriques, Huang et al. 2004).
Testosterone was found to be the primary mediator of higher AAA prevalence in
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adult AngII-infused male mice (Henriques, Huang et al. 2004; Henriques, Zhang
et al. 2008). As a mechanistic target of testosterone to promote AngII-induced
AAAs, AT1aR mRNA abundance was greater in abdominal compared to thoracic
aortas of male, but not female mice, and this regional difference was abolished
by orchiectomy and restored in castrated males by androgen administration
(Henriques, Zhang et al. 2008).
Vascular wall cells along the aortic length derive from different embryonic
origins that exhibit distinct sensitivity to testosterone during development (Cunha,
Shannon et al. 1981; Majesky 2007; Wasteson, Johansson et al. 2008). For
example, smooth muscle of the abdominal aorta, where AT1aR expression is
pronounced in males, derives from mesenchymal cell origin, and this embryonic
cell type exhibits androgen receptor (AR) activity (Cunha, Shannon et al. 1981;
Majesky 2007; Wasteson, Johansson et al. 2008). It is unclear whether AR
stimulation of mesenchymal cells during developmental testosterone surges
contributes to regional differences in AT1aR expression in aortas of adult males
and impacts AAA susceptibility. Exposure of females during the neonatal period
to testosterone has been used previously to induce male-like, or androgenized,
behaviors (Pfaff and Zigmond 1971; Hrabovszky and Hutson 2002; Wallen
2005). This method, which imposes upon females exposure to testosterone
shortly after birth, mimics developmental effects of androgen in males during the
neonatal period (Motelica-Heino, Castanier et al. 1988; Corbier, Edwards et al.
1992). In this study, we sought to define effects of exposure of neonatal females
to testosterone on regional expression of aortic AT1aR and susceptibility to
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AngII-induced vascular diseases as adults. Remarkably, we found that exposure
of neonatal female mice to a single dose of testosterone increased AT1aR
mRNA abundance specifically in abdominal aortas of adult females. In addition,
females exposed to testosterone as neonates exhibited a striking increase in
adult susceptibility to AngII-induced AAAs, atherosclerosis and ascending aortic
aneurysm. Deficiency of AT1aR in smooth muscle cells reduced effects of
neonatal testosterone to promote AngII-induced AAAs in adult females, but had
no effect on atherosclerosis or ascending aortic aneurysm. Our findings indicate
that during a critical period of neonatal development transient exposure to
testosterone in females is capable of developmentally programming enhanced
susceptibility to three different AngII-induced vascular pathologies through
distinct mechanisms.
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4.3

Methods

4.3.1 Aminals
Female ApoE-/- and LDLR-/- mice (N10 C57BL/6 background) were bred
to males in house. Within 24 hours of birth, female mice were injected once with
either vehicle (corn oil) or testosterone propionate (400 µg/mouse, s.c., Sigma
Aldrich, St. Louis, MO). At 3 months of age, female ApoE-/- and LDLR-/- mice
were sacrificed for aortic gene expression analysis. Age-matched ApoE-/females were infused with saline or AngII (500, 750 or 1,000ng/kg/min, Bachem,
Torrance, CA) by osmotic pumps (Alzet, model 1004, Durect Co., Cupertino, CA)
for 4 weeks. Female ApoE-/- and LDLR-/- mice were maintained on standard
diet through the study.
AT1aRSM22 KO and littermate controls AT1aRfl/fl mice were generated and
bred as previously described. Within 24 hours of birth, female AT1aRfl/fl and
AT1aRSM22 KO mice were injected once with either vehicle (corn oil) or
testosterone propionate (400 µg/mouse, s.c.). At 3 months of age, females were
infused with saline or AngII (1,000ng/kg/min, Bachem, Torrance, CA) by osmotic
pumps for 4 weeks as previously described. The mice were fed a high fat diet
containing 21% milk fat and 0.2% cholesterol (TD88137, Harlan Teklad,
Indianapolis, IN) 1 week prior to pump implantation and through study endpoint.
All experiments were performed in accordance with the University of Kentucky
Institutional Animal Care and Use Committee.
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4.3.2 Measurement of systolic blood pressure
Systolic blood pressures were measured one week prior to osmotic mini
pump implantation and during the third week of AngII infusion using a
noninvasive tail-cuff system (BP-2000 Blood Pressure Analysis System, Visitech
Systems).

4.3.3 Quantification of Atherosclerosis, AAA and Ascending Aortic Aneurysm
Atherosclerotic lesions were quantified in the aortic arch and root as
described previously. Aortic roots from representative samples (n=5/group) were
sectioned and immunostained for CD68 (5 μg/mL; rat monoclonal ab53444,
Abcam, Cambridge MA). AAA incidence was quantified by 3 independent
observers blinded to the experimental design as described previously (Daugherty
and Cassis 1999; Daugherty, Manning et al. 2000). Abdominal aortic lumen
diameter measurements were made on anesthetized mice using high-resolution
ultrasound (Visualsonics, Vevo 660) at baseline, day 7, day 14 and day 28 of
AngII infusion. Maximal diameters of abdominal aortas were measured on
cleaned, formalin-fixed aortas by ImagePro Plus software (Media Cybernetics).
AAAs were defined as > 50% dilation of lumen diameters from saline-infused
mice.
The extent of ascending aortic dilation as an index of aortic arch
aneurysms was quantified by measuring aortic arch intimal areas (to 3 mm distal
to the subclavian branch) and ascending aortic diameters (Daugherty, Rateri et al.
2010). Representative ascending aortic aneurysms (n=4-5/group) were sectioned
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and stained with H&E, and macrophages (Accurate Chemical, catalog No.
AIAD31240, dilution 1:1000). Stained sections were magnified and
photographed using a Nikon Eclipse 80i microscope and digital camera. Medial
thickness was measured on H&E stained sections.

4.3.4 Aneurismal Tissue Characterization
To compare AAAs between different groups, three suprarenal aortas
(closest to the mean external diameter of each group) were chosen for vascular
characterization. Briefly, cleaned, formalin-fixed aortas were injected with
Tissue-Tek® O.C.T. (Optimal Cutting Temperature) compound (Ted Pella, Inc.,
Redding, CA). The suprarenal aorta segment containing AAA was embedded in
O.C.T. compound and serially sectioned using a cryostat as previously
describled (Police, Putnam et al. 2010). Sections were fixed with absolute alcohol
and stained with hematoxylin and eosin (H&E), and Movat’s staining for vascular
characterization.

4.3.5 Blood Analysis
Blood was obtained from the right ventricle of anesthetized mice
(ketamine/xylazine, 100/10 mg/kg, ip) for measurement of monocyte and red
blood cell counts (Hemavet, Drew Scientific Group, Dallas, TX). Total serum
cholesterol concentrations were measured from individual mice using enzymatic
assay kits (Wako Pure Chemical, Catalog No. 439-17501). Serum samples (50 ul;
n = 5) were fractionated by size exclusion chromatography (Daugherty, Manning
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et al. 2000), and cholesterol concentrations determined using enzymatic kits.
Serum testosterone concentrations and plasma aldosterone concentrations were
determined using commercial RIA DSL-4000 and RIA DSL-8600 kits,
respectively (Diagnostic Systems, Inc.).

4.3.6 Aortic gene quantification by Real Time PCR
Thoracic (aortic arch to diaphragm) and abdominal aortas (diaphragm to
ileal bifurcation) were harvested from age-matched adult female mice. Aorta
samples were stored in RNA Later (Ambion, Austin, TX) and cleaned of all
adherent tissue. Total RNA was extracted using Rneasy Fibrous Minikit (Qiagen,
Alameda, CA) (Henriques, Zhang et al. 2008). For in vitro experiments, primary
mouse vascular smooth cells (passage 7-10) were treated with 10nM of
testosterone propionate (Sigma Aldrich, St. Louis, MO) in 0.1% DMSO for 24
hours. Total RNA was extracted with Trizol (Invitrogen, Carlsbad, CA). All RNA
samples were treated with Turbo DNA-free (Ambion, Austin, TX) to remove
genomic DNA. RNA quantity was assessed spectrophotometrically, and quality
was evaluated using a Bio-Rad Experion Automated Electrophoresis System
(Bio-Rad, Hercules, CA). Mouse AT1aR primers were obtained from Qiagen
(Alameda, CA). Relative quantification of aortic AT1aR mRNA abundance was
performed using a BioRad iCycler (BioRad, Hercules, CA) (Henriques, Zhang et
al. 2008). 18S rRNA was used to normalize for loading and data are expressed
as AT1aR/18S ratios.
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Customized PCR arrays were obtained from SABioscience (Frederick, MD)
to test 43 genes that have been recently reported to differentially expressed in
the between AAA-prone and non AAA-prone aortic segments in male ApoE-/mice (Rush, Nyara et al. 2009). After total RNA samples were extracted from
thoracic and abdominal aortas, reverse transcription and subsequent PCR
reactions were performed using RT² First Strand Kit and RT² qPCR Master Mixes
respectively, based on manufacturer recommendation (SABioscience, Frederick,
MD).

4.3.7 Statistical Analysis
Data are represented as mean ± SEM. Comparison of AAA incidence
between groups was analyzed using Fisher’s exact test. Unpaired student’s t test
was used to compare parametric data on two groups. Multiple groups were
analyzed with 2-way ANOVA followed by Tukey’s test for more than two groups.
Analyses were performed using Sigmastat. Statistical significance was defined
as P<0.05.
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4.4

Results

4.4.1 Neonatal testosterone exposure developmentally programs increased
AT1aR expression in abdominal aortas from adult female hyperlipidemic
mice
Previous results demonstrated a requirement for AT1aR in AngII-induced
atherosclerosis and AAA formation in adult male mice (Daugherty, Rateri et al.
2004; Cassis, Rateri et al. 2007). Recent studies demonstrated greater AT1aR
mRNA abundance in abdominal compared to thoracic aortas of male, but not
female ApoE-/- mice (Henriques, Zhang et al. 2008). Moreover, androgenmediated regulation of AT1aR mRNA abundance in abdominal aortas of male
and female ApoE-/- mice paralleled susceptibility to AngII-induced AAAs
(Henriques, Zhang et al. 2008). Therefore, we determined if testosterone
administration to neonatal females imparted regional differences in AT1aR
expression along the aortic length in adult females. We examined two
hypercholesterolemic strains of female mice to determine if background genetics
influenced developmental effects of testosterone. As reported previously
(Henriques, Zhang et al. 2008), adult female ApoE-/- or LDLR-/- mice
administered vehicle as neonates exhibited a similar AT1aR mRNA abundance
in thoracic compared to abdominal aortas (Figure 4.1). In contrast,
administration of testosterone to neonatal females increased AT1aR mRNA
abundance in abdominal, but not thoracic aortas of adult female mice (P<0.001)
(Figure 4.1). Thus, similar to observed results previously in males (Henriques,
Zhang et al. 2008), exposure of neonatal female mice to testosterone imparted
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increased localization of AT1aR mRNA expression specifically to abdominal
aortas of adult females. However, unlike males, increased abundance of AT1aR
mRNA in adult females exposed neonatally to testosterone persisted even
though adult females exhibited low serum concentrations of testosterone (Table
4.1).
A recent study utilizing whole genome expression analysis has
demonstrated that over 300 transcripts are differentially expressed between
AAA-prone and non AAA-prone aortic segments in male ApoE-/- mice (Rush,
Nyara et al. 2009). To test if any of these genes were regulated by neonatal
testosterone, we selected 43 gene targets and performed PCR array analysis to
examine their mRNA expression levels along the length of the aorta. Interestingly,
mRNA abundance of neutrophil cytosolic factor 1 (Ncf1, a component of NADPH
oxidase) in thoracic aortas, and aryl hydrocarbon receptor nuclear translocatorlike (Arntl) in both thoracic and abdominal aortas were significantly increased in
adult females administered testosterone as neonates (Figure 4.14),

4.4.2 Administration of testosterone to neonatal female ApoE-/- mice increases
AngII-induced AAAs in adult females.
Since previous studies demonstrated that AngII-induced AAAs are
promoted by a hypercholesterolemic environment in male mice (Daugherty and
Cassis 1999; Daugherty, Manning et al. 2000), initial studies were performed in
hypercholesterolemic female mice. Female ApoE-/- mice were administered a
single dose of testosterone or vehicle within the first 24 hours after birth to mimic
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neonatal testosterone surges in males (Motelica-Heino, Castanier et al. 1988;
Corbier, Edwards et al. 1992), and then adult female ApoE-/- mice were infused
with different doses of AngII. Neonatal administration of testosterone resulted in
a modest but significant increase in body weight in adult females but had no
effect on serum cholesterol concentrations, blood pressure, blood monocyte
counts (Table 4.1) or serum lipoprotein cholesterol distribution (Figure 4.5).
Moreover, serum testosterone concentrations were not elevated in adult female
mice administered testosterone as neonates (Table 4.1), and were 7-fold less
than those observed previously in adult male ApoE-/- mice (Henriques, Huang et
al. 2004).
Infusion of AngII to adult females administered vehicle as neonates
resulted in modest but significant increases in abdominal aortic lumen and
external diameters, indicative of aneurysm formation in a small percentage of
mice (Figure 4.2-4.4). AAA incidence, which included mice that died from
aneurismal rupture, was increased dose-dependently by AngII in female mice
administered vehicle as neonates, but did not rise above 20% at the highest dose
(1,000 ng/kg/min) of AngII infusion (Figure 4.3). Notably, adult female mice that
were exposed to testosterone as neonates exhibited striking increases in
abdominal aortic lumen dilation (1.29 ± 0.10 vs. 1.69 ± 0.11mm; P<0.01) and
external diameters (1.31 ± 0.115 vs. 1.85 ± 0.16mm; P<0.01) at the highest dose
(1,000 ng/kg/min) of AngII infusion, with pronounced aneurismal pathology
similar to that previously observed in adult males (Manning, Cassis et al. 2002;
Henriques, Huang et al. 2004) (Figure 4.3, 4.4). AAA incidence was greater at
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each dose of infused AngII in adult females administered testosterone as
neonates compared to vehicle controls (Figure 4.2), with a 3-fold increase in AAA
incidence at the infusion dose of 1,000 ng/kg/min of AngII (21% vs. 64%;
P<0.05). An increase in mortality from aneurismal rupture contributed to higher
AAA incidences in females administered testosterone as neonates (rupture:
vehicle, 7%; testosterone, 20%; NS).

4.4.3 Neonatal testosterone exposure developmentally programs AngII-induced
atherosclerosis and ascending aortic aneurysms in female LDLR-/- mice
independent of smooth muscle AT1aR
Since smooth muscle cell AT1aRs were pivotal in androgen promotion of
AngII-induced AAAs in adult females, we determined if smooth muscle AT1aR
deficiency influenced effects of neonatal testosterone to promote AngII-induced
vascular pathologies in adult females. In addition, we quantified ascending aortic
aneurysms (Daugherty, Rateri et al. 2010) and atherosclerosis (Daugherty,
Manning et al. 2000) as additional vascular pathologies induced by infusion of
AngII that do not exhibit sex differences between adult males and females (21,
unpublished observations). Female AT1aRfl/fl control and AT1aRSM22 KO mice
were administered a single dose of vehicle or testosterone at 1 day of age, and
then infused with AngII at 3 months of age. Neonatal administration of
testosterone, as well as smooth muscle cell AT1aR deficiency, had no effect on
baseline systolic blood pressures, AngII-induced hypertension, plasma
aldosterone concentrations, serum cholesterol concentrations (Table 4.2) or
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serum lipoprotein cholesterol distributions (Figure 4.6). Moreover, serum
testosterone concentrations did not differ across study groups (Table 4.2). In
females administered vehicle as neonates, AT1aRSM22 KO had no effect on
AngII-induced atherosclerosis in the aortic arch or aortic root (Figure 4.7).
Interestingly, administration of testosterone to neonatal female mice resulted in
pronounced increases in AngII-induced atherosclerosis in both AT1aRfl/fl (11.3 ±
1.1 vs. 16.3 ± 1.6 %; P<0.01) and AT1aRSM22 KO (10.4 ± 1.0 vs. 14.9 ± 1.5 %;
P<0.05) adult female mice (Figure 4.7). Lesional macrophages, as evidenced by
quantification of CD68 immunostaining in aortic root sections from adult females,
were increased by neonatal administration of testosterone (Figure 4.8).
However, deficiency of AT1aR in smooth muscle cells did not influence the ability
of neonatal testosterone administration to promote AngII-induced atherosclerosis
(Figure 4.7, 4.8).
In addition to promoting atherosclerosis, neonatal testosterone
administration to female LDLR-/- mice augmented AngII-induced increases in
ascending aortic diameters (P<0.05) (Figure 4.9A) and ascending aortic intimal
areas (P<0.05) (Figure 4.9B), indicative of aortic arch aneurysms. Cross
sections from ascending aortas of female mice exposed to testosterone as
neonates and then infused with AngII as adults exhibited medial thickening
(P<0.001) (Figure 4.10) and aortic ulceration (P<0.05) (Figure 4.11).
Macrophage immunostaining was prominent in media and adventitia of aortic
arch sections from AngII-infused adult female mice administered testosterone as
neonates (P<0.05) (Figure 4.10), similar to results previously observed in aortic
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arches of adult male mice (Daugherty, Rateri et al. 2010). Deficiency of AT1aR
in smooth muscle did not influence the ability of neonatal testosterone
administration to promote AngII-induced aneurysms in the aortic arch (Figure
4.9-4.11).

4.4.4 Smooth muscle AT1aR deficiency attenuates neonatal testosterone
programming of AngII-induced AAAs in adult female LDLR-/- mice
Similar to findings in ApoE-/- females exposed neonatally to testosterone,
adult AT1aRfl/fl females administered testosterone as neonates exhibited a
striking increase in AngII-induced AAAs (AAA incidence, 15 vs. 64 %, P<0.001;
Maximal external abdominal aortic diameter, 0.98 ± 0.10 vs. 1.55 ± 0.09 mm,
P<0.001) (Figure 4.12,). Interestingly, smooth muscle cell specific AT1aR
deficiency reduced, but did not ablate effects of neonatal testosterone to promote
AngII-induced AAAs (AAA incidence, 64 vs. 33 %, P<0.05; Maximal external
abdominal aortic diameter, 1.55 ± 0.09 vs. 1.22 ± 0.12 mm, P<0.05) (Figure
4.12). The magnitude of effect of smooth muscle AT1aR deficiency to reduce
AngII-induced AAAs was similar between neonatal and adult females exposed to
androgen (Figure 4.12A vs Figure 3.8). We examined tissue characteristics of
AAAs of equivalent sizes that formed in female mice of each genotype exposed
to neonatal testosterone. AAAs that formed in both groups exhibited typical
characteristics of medial elastin degradation and pronounced thrombus in the
adventitia (Figure 4.13). These data demonstrate that exposure of neonatal
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females to testosterone increases adult susceptibility of females to AngII-induced
AAAs partially through smooth muscle cell AT1aR.
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4.5

Discussion
Our findings reveal that neonatal exposure of female mice to testosterone

developmentally programs three distinct AngII-induced vascular pathologies,
namely atherosclerosis, ascending arch aneurysms, and AAAs. As a mechanism
contributing to sex differences in AngII-induced AAAs between adult males and
females (Manning, Cassis et al. 2002; Henriques, Huang et al. 2004), exposure
of neonatal females to testosterone developmentally programs a regional
increase in abdominal aortic AT1aR mRNA abundance. To gain insights into the
cell target of testosterone during development to increase aortic AT1aR mRNA
abundance and enhance AngII-induced vascular pathologies, we performed
studies in female mice lacking AT1aR in smooth muscle cells. Smooth muscle
deficiency of AT1aR reduced neonatal effects of testosterone to promote AngIIinduced AAAs, but had no effect on augmented atherosclerosis or aortic arch
aneurysms. These results demonstrate that distinct mechanisms mediate effects
of developmental testosterone to enhance three different AngII-induced vascular
pathologies in adult females. These studies are the first to demonstrate that sex
hormone exposures during development can markedly alter vascular disease
susceptibility in adults.
Exposure of neonatal females to testosterone, designed to mimic a surge
of testosterone in males shortly after birth (Motelica-Heino, Castanier et al. 1988;
Corbier, Edwards et al. 1992), has been used by several investigators to study
sexual differentiation of the brain. Permanent changes in brain neurons of
females androgenized during development are considered to be “organizational”,
122

allowing for male-like behaviors that persist to adulthood (Arnold 2009). In
contrast to studies focused on brain, little is known about developmental effects
of sex hormones on other traits. We focused on effects of sex hormones during
development on regional variations in AT1aR abundance in aortas since previous
studies demonstrated a critical requirement of AT1aR for all three AngII-induced
vascular pathologies (Cassis, Rateri et al. 2007; Daugherty, Rateri et al. 2010).
Moreover, previous results demonstrated higher expression of AT1aR in
abdominal compared to thoracic aortas of male but not female mice (Henriques,
Zhang et al. 2008). In this study we demonstrated that administration of
testosterone to neonatal female mice initiated greater abdominal aortic AT1aR
mRNA abundance and markedly enhanced AAA formation in adult females.
Interestingly, unlike males (Henriques, Huang et al. 2004; Henriques, Zhang et
al. 2008), exposure of neonatal females to testosterone resulted in long-lasting
effects that persist into adulthood and did not require the continued presence of
circulating testosterone. Thus, similar to effects of testosterone to permanently
influence brain behaviors (Arnold 2009), aortic AT1aR abundance and AAA
susceptibility can be programmed developmentally by testosterone and
sustained in adulthood with low circulating testosterone in females.
In mice, aortic smooth muscle cells are highly heterogeneous. The
diversity of smooth muscle cell embryonic origins has been suggested to
contribute to region-specific aortic pathologies, including those induced by
infusion of AngII (Majesky 2007; Tromp, Kuivaniemi et al. 2010). For example,
thoracic and abdominal aortic smooth muscle cells respond distinctively to
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transforming growth factor-β (TGF-β) (Topouzis and Majesky 1996). Inhibition of
TGF-β has a beneficial effect in a mouse model of ascending aortic aneurysms
while TGF-β protects against aortic dissection of AngII-induced AAAs (Habashi,
Judge et al. 2006; Wang, Ait-Oufella et al. 2010). Our results demonstrate that
thoracic and abdominal aortas differ in the regulation of expression of AT1aR,
and that effects of testosterone to increase aortic AT1aR expression were
specific to abdominal aortas. Recent results demonstrated that infusion of AngII
to C57BL/6 male mice resulted in hyperplasia of smooth muscle cells in the
ascending aorta, but hypertrophy of smooth muscle in other aortic regions
(Owens, Subramanian et al. 2010). Interestingly, despite differences in AT1aRmediated regulation of vascular smooth muscle growth along the aortic length, all
growth-related responses of aortic smooth muscle to AngII were abolished in
AT1aR deficient mice (Owens, Subramanian et al. 2010). Our results
demonstrate that even though testosterone promoted a region-specific increase
in AT1aR mRNA abundance to abdominal aortas, all three AngII-induced
pathologies were increased in neonatal females exposed to testosterone. While
smooth muscle cell specific deficiency of AT1aR reduced effects of testosterone
to promote AngII-induced AAAs, aortic arch aneurysms and atherosclerosis were
not influenced by AT1aR on this cell type. Moreover, our results demonstrate
that neonatal testosterone exposure increase mRNA abundance of neutrophil
cytosolic factor 1 (Ncf1, a component of NADPH oxidase) in thoracic aortas, and
aryl hydrocarbon receptor nuclear translocator-like (Arntl) in both thoracic and
abdominal aortas of adult females (Figure 4.14), indicating that multiple genes
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can be modulated by developmental androgen in a regional specific manner.
These results demonstrate that distinct mechanisms, regulated differentially by
testosterone, contribute to AngII-induced initiation of these vascular pathologies.
In contrast to AAAs, previous findings from our laboratory do not support
sex differences in AngII-induced atherosclerosis (Henriques, Zhang et al. 2008).
Moreover, aortic arch aneurysms occur at similar levels between adult male and
female hyperlipidemic mice infused with AngII (unpublished observations). Our
results demonstrate that even though adult males and females do not exhibit
robust sex differences in these two AngII-induced vascular pathologies,
androgenization of females during development programmed increases in
atherosclerosis and aortic arch aneurysms. These results suggest that male and
female mice differ in their response to testosterone during the neonatal period of
development. Unfortunately, technical difficulties preclude measurement of
testosterone concentrations in neonatal female mice to determine if levels of
testosterone in androgenized females are different than those normally
experienced by neonatal males. It is conceivable that the dose (400 µg) of
testosterone administered to neonatal females exceeded levels experienced by
males, resulting in increased susceptibility to pathologies that do not typically
exhibit sex differences. Alternatively, recent studies demonstrated that sex
chromosomes contribute to differences in AngII-induced hypertension between
male and female mice (Ji, Zheng et al. 2010). An ability of neonatal testosterone
to mediate increased AngII-induced atherosclerosis and aortic arch aneurysms in
adult females may have arisen from sex chromosome effects. Future studies
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examining sex chromosome effects on AngII-induced vascular pathologies may
reveal a role for sex chromosomes as contributors to differences in effects of
neonatal testosterone in males compared to females.
In conclusion, these data demonstrate that developmental
androgenization of female mice confers increased susceptibility to AngII-induced
AAAs, atherosclerosis and ascending aortic aneurysms as adults. An ability of
testosterone to developmentally program three distinct vascular pathologies in
females indicates that short term hormonal exposures can markedly impact
vascular disease susceptibility of adults. Based on these findings, targeting of
specific environmental risk factors during development may provide new insights
into the prevention, diagnosis and treatment of these life-threatening vascular
diseases.
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Table 4.1 Characteristics of female ApoE-/- mice subjected to neonatal administration with either vehicle or testosterone.

Group

BW (g)

Liver (%BW)

Serum testosterone
(pg/ml)

Vehicle

22.0±0.4

4.63±0.08

133±9

1.92±0.37

8.01±0.38

Testosterone

23.5±0.3*

4.95±0.08*

94±9

2.24±0.32

8.75±0.40

WBC (K/µl) RBC (M/µl)

Systolic blood pressure (mmHg)
Total serum
cholesterol
(mg/dl)

baseline

500
ng/kg/min
AngII

750
ng/kg/min
AngII

1000
ng/kg/min
AngII

Vehicle

123±3

130±5

148±3**

160±6**

368.1±19.5

Testosterone

120±2

133±8

142±5**

159±8**

351.7±18.3

Group

Data are represented as mean + SEM from n = 20-25 mice/group.
*P<0.01 compared to vehicle group.
**P<0.001 compared to baseline measurement within treatment (vehicle, testosterone).
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Table 4.2 Characteristics of adult female AT1aRfl/fl and AT1aRSM22 KO administered vehicle or testosterone as neonates.
Total
Serum

Systolic blood
Plasma

serum
Groups

N

BW(g)

testosterone

pressure (mmHg)
aldosterone

cholesterol
(pg/ml)

(pg/ml)
(mg/dl)

baseline

AngII

AT1aRfl/fl + vehicle

26

24.0 ± 0.6

185±28

1412 ± 136

739 ± 131

121 ± 4

154 ± 8**

AT1aRSM22 KO + vehicle

22

24.4 ± 0.4

142±16

1456 ± 181

601 ± 123

112 ± 5

150 ± 8**

AT1aRfl/fl + testosterone

33

26.6 ± 0.6*

155±15

1424 ± 119

548 ± 125

115 ± 3

156 ± 4**

AT1aRSM22 KO + testosterone

18

27.0 ± 0.7*

130±20

1414 ± 147

456 ± 77

116 ± 6

153 ± 8**

Data are represented as mean + SEM.
*P<0.001 compared to vehicle group within genotype. **P<0.001 compared to baseline blood pressure.
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A

ApoE-/-

AT1aR/18s ratio

0.05

thoracic
abdominal

0.04

*,**

0.03

*

0.02

0.01

0.00
vehicle

B

testosterone
LDLR-/-

0.25

thoracic
abdominal

*,**

AT1aR/18s ratio

0.20

*
0.15

0.10

0.05

0.00
vehicle

testosterone

Figure 4.1 AT1aR mRNA abundance in adult female ApoE-/- mice (A) (n = 810/group) and LDLR-/- mice (B) (n = 5-6/group) administered testosterone as
neonates. *, P < 0.001 compared to vehicle group within aortic region; **,
P<0.001 compared to thoracic within treatment.
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Figure 4.2 Neonatal testosterone administration significantly increases AngIIinduced AAAs in adult female ApoE-/- mice. (A) Representative aortas from each
AngII-infused group; scale bar, 2 mm. (B) AAA incidences in mice infused with
500, 750 or 1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to 500
ng/kg/min AngII infused group within testosterone treatment; **, P<0.05
compared to vehicle within 1000 ng/kg/min AngII-infused group.
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Abdominal aortic lumen diameter (mm)

3.0

2.5

*,
†,**

2.0

*

1.5

1.0

0.5
vehicle testosterone vehicle testosterone vehicle testosterone
500 ng/kg/min AngII

750 ng/kg/min AngII

1000 ng/kg/min AngII

Figure 4.3 Neonatal testosterone administration significantly increases abdominal
aortic lumen diameters in adult female ApoE-/- mice infused with 500, 750 or
1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to 500 ng/kg/min
AngII infused group within treatment; †, P<0.05 compared to 750 ng/kg/min AngII
infused group within testosterone treatment; **, P<0.05 compared to vehicle
within 1000 ng/kg/min AngII-infused group. Triangles represent measurements
from individual mice, circles represent mean ±SEM.
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Maximal external abdominal diameter (mm)

3.5

3.0

2.5

*,**

2.0

1.5

1.0

0.5
vehicle

testosterone

500 ng/kg/min AngII

vehicle

testosterone

750 ng/kg/min AngII

vehicle

testosterone

1000 ng/kg/min AngII

Figure 4.4 Neonatal testosterone administration significantly increases maximal
external diameters of the abdominal aortas in adult female ApoE-/- mice infused
with 500, 750 or 1000 ng/kg/min AngII (n=14-25/group). *, P<0.05 compared to
500 ng/kg/min AngII infused group within treatment; **, P<0.01 compared to
vehicle within 1000 ng/kg/min AngII-infused group. Triangles represent
measurements from individual mice, circles represent mean ±SEM.
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Figure 4.5 Serum lipoprotein cholesterol distributions in AngII-infused female
ApoE-/- mice administered with either vehicle or testosterone as neonates.
Neonatal testosterone administration does not alter lipoprotein profiles in adult
female mice. Data are the mean ± SEM of 5 individual mice per group.
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atherosclerosis in adult AT1aRfl/fl and AT1aRSM22 KO female LDLR-/- mice. (A)
Atherosclerotic lesion formation (% intimal surface area) in the aortic arch.
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CHAPTER V. GENERAL DISCUSSION

5.1

Summary
The purpose of this study is to examine the hypothesis that androgen

promotes AT1aR expression on SMC to confer high prevalence of AngII-induced
AAAs in hyperlipidemic mice. In addition, we also investigate the role of
endogenous androgen in the progression of established AngII-induced AAAs in
male mice.
First, we sought to examine the role of endogenous androgen in the
growth of established AngII-induced AAAs in male mice. Since previous studies
demonstrated that removal of endogenous androgen markedly reduced AAA
formation in male mice (Henriques, Huang et al. 2004), we hypothesized that
removal of endogenous androgen would also decrease the progressive
expansion of established AAAs. Interestingly, castration significantly decreased
the progressive lumen dilation of established AngII-induced AAAs in male ApoE/- mice, but had no effect on external AAA diameters. These results suggest that
androgen contributes to the progression of established AAAs through distinct
mechanisms that differentially influence aortic lumen and wall diameters.
Next, we investigated if androgen regulates aortic AT1aR expression to
promote AngII-induced AAA formation. We hypothesized that androgen promotes
AT1aR expression on SMC to confer higher susceptibility of AngII-induced AAAs
in male mice. Our data demonstrated that in male and female mice, both
endogenous and exogenous androgen stimulate AT1aR level particularly in
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abdominal aortas where AngII-induced AAAs are usually located. This androgendependent enhanced mRNA abundance of abdominal aortic AT1aR was highly
associated with increased AngII-induced AAA formation in male and female
mice. To further examine if AT1aR on SMC were regulated by androgen to
confer high prevalence of AngII-induced AAA formation in mice, we utilized mice
with SMC specific AT1aR deficiency to determine the role of SMC AT1aR in
enhanced AngII-induced AAA formation in female hyperlipidemic mice
administered exogenous androgen. SMC AT1aR deficiency significantly reduced
luminal and external diameters of abdominal aortas as well as the incidence of
AngII-induced AAAs. Collectively, these results indicate that in adult mice
androgen stimulate SMC AT1aR expression to promote AngII-induced AAA
formation.
Furthermore, we determined the role of androgen during development on
AT1aR expression on SMC and AngII-induced AAA formation in adult female
hyperlipidemic mice. We hypothesized that neonatal androgen administration in
female mice stimulates aortic SMC AT1aR expression and results in increased
susceptibility of AngII-induced AAAs in adulthood. Our data demonstrated that
neonatal testosterone administration dramatically increased AngII-induced AAA
formation in adult female mice and this was associated with long-lasting
enhanced AT1aR expression specifically in abdominal aortas. In addition,
deficiency of SMC AT1aR reduced effects of neonatal testosterone
administration. AngII-induced atherosclerosis and ascending aortic aneurysms
were also enhanced by neonatal administration of testosterone while SMC
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AT1aR deficiency had no effect on the pathogenesis of these two AngII-induced
vascular pathologies.In summary, these results demonstrated that androgen,
both in adult life and during development, stimulates SMC AT1aR expression
and promotes AngII-induced AAA formation in adult female hyperlipidemic mice.

5.2

Potential mechanisms of androgen to influence the development of AngIIinduced AAAs

5.2.1 The role of androgen during adult life in AngII-induced AAA formation and
progression
In humans, male gender is a strong independent risk factor of AAA. A
similar gender difference has been observed in the experimental model of AngIIinduced AAA. In agreement with previous findings, results from this study confirm
a critical role for testosterone as a primary mediator of gender differences in the
pathogenesis of AngII-induced AAA. It has been demonstrated that removal of
endogenous androgen profoundly reduced AngII-induced AAA formation in male
ApoE-/- mice (Henriques, Huang et al. 2004). Our laboratory also demonstrated
that exogenous androgen administration can restore a high incidence of AngIIinduced AAA in castrated male mice and also stimulate AAA formation in female
mice (Henriques, Zhang et al. 2008). Interestingly, estrogen has been reported to
exert protective effects against AAA development. For example, others
demonstrated that male mice administered supraphysiological level of estrogen
exhibited a significant reduction in AngII-induced AAA formation (Martin-McNulty,
Tham et al. 2003) and a similar finding has been observed in male rats infused
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with elastase in the abdominal aorta to induce aortic dilation (Ailawadi, Eliason
et al. 2004; Cho, Woodrum et al. 2009) . The removal of endogenous estrogen
was shown to enhance AAA incidence of female rats in elastase infusion induced
AAAs (Wu, Zhang et al. 2009), but not in others (Cho, Woodrum et al. 2009).
However, most studies indicate that testosterone promotes AAA formation in
different models of this disease, including AngII-induced AAAs.
To investigate mechanisms of androgen in promoting AngII-induced AAA
formation, we hypothesized that androgen increases the expression of AT1aR in
the abdominal aorta to confer a higher prevalence of AAA in male mice. This was
primarily due to the observation that deficiency of AT1aR totally ablates AngIIinduced AAA formation in male mice, suggesting AT1aR is required for AAA
development (Cassis, Rateri et al. 2007). In addition, bone marrow
transplantation studies revealed that AT1aR on monocytes may not be involved
in AngII-induced AAAs, indicating a potential role of AT1aR on resident cells
presumably vascular wall cells of the abdominal aorta as targets of testosterone
and/or AngII (Cassis, Rateri et al. 2007). Indeed, in these studies we
demonstrate that in both male and female ApoE-/- mice, androgen positively
regulates the mRNA abundance of AT1aR in abdominal, but not thoracic aorta
(Chapter III). In the presence of androgen, either endogenous or exogenous, the
increased level of abdominal aortic AT1aR is highly correlated with higher
prevalence of AngII-induced AAAs in male and female mice. In contrast, the
region specific pattern of aortic AT1bR was not altered by endogenous or
exogenous androgen. Differences in the promoters of AT1aR and AT1bR genes
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may contribute to androgen-specific effects to increase AT1aR mRNA
abundance. We have performed a preliminary scan of the rat AT1 receptor
promoter for potential transcription factor binding sites using Genomatix
database. Several putative androgen response elements (AREs) binding sites
were identified at around 515, 2660 and 2826 upstream of the transcription start
site. In addition, it has been reported that the actions of AR coregulators also
depend on the state of chromatin at the loci of target genes. For example, one of
the AR coregulators, CBP acts as a corepressor of AR when recruited to
pericentric regions, but as a coactivator when recruited to euchromatin (Zhao,
Takeyama et al. 2009). AT1aR and AT1bR are encoded by two distinct genes
located on two different chromosomes. It is possible that the differences in the
context of chromatins at AT1aR and AT1bR loci may contribute to the specific
stimulatory effect of androgen on AT1aR expression. In humans, there is one
gene encoding the AT1 receptor. DHT increased AT1 receptor mRNA and
protein levels in androgen-dependent human prostate cancer cells (Uemura,
Hasumi et al. 2006). These results suggest that testosterone positive regulation
of AT1 receptor expression is not restricted to mice. However, no studies have
examined whether human AT1 receptors are differentially expressed between
thoracic and abdominal aorta.
It has been previously reported AR are expressed at lower levels in the
vasculature of female compared to male rats (Higashiura, Mathur et al. 1997).
However, our results demonstrate that female ApoE-/- mice express abundant
ARs in abdominal aortas and can respond to exogenous androgen similar to
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males. Interestingly, our results also demonstrate that similar to AT1aR
expression, the abdominal aortas of male and female ApoE-/- mice express
higher levels of AR compared to the thoracic region. Collectively, these results
demonstrate marked heterogeneity of the aorta along its length in males and
females, with sex hormones contributing to differential expression of some of
these region-specific genes.
Furthermore, we utilized SMC AT1aR deficient mice to confirm that
androgen positively regulates the expression of AT1aR on smooth muscle cells
and promotes AngII-induced AAA formation. Deficiency of SMC AT1aR resulted
in a 35% reduction of AAA incidence from 85% to 50% in adult female mice
administered exogenous androgen. Although this significant 35% reduction
suggests a pivotal role SMC AT1aR in AAA development, deficiency of SMC
AT1aR did not totally ablate the effect of exogenous androgen on AngII-induced
AAA formation in female mice. These results suggest that androgen may
regulate AT1aR level on other cells in the vasculature, such as endothelial cells
or fibroblasts in the adventitia, to promote AAA formation. Alternatively, there
may be other potential mechanisms for androgen regulation of gender
differences in AngII-induced AAA formation. For example, androgen has been
demonstrated to stimulate MMP-2 expression in prostate cancer cells (Liao,
Thrasher et al. 2003). Recently it has been demonstrated that male rats exhibit
increased MMP-13 mRNA expression and proteins level in the aortic tissues as
well as larger AAA compared to females in the experimental model of elastase
infusion induced AAAs (Cho, Roelofs et al. 2009).

148

Overall, our studies demonstrate that AT1aR plays a critical role in the
development of AngII-induced AAAs and is an important mechanism by which
androgen mediates gender differences in experimental AAAs. Indeed,
administration of losartan, an AT1 receptor inhibitor, fully protects male mice from
developing AngII-induced AAAs (Daugherty, Manning et al. 2001). Recently, it
has also been reported that AT1 receptor inhibition reduces macrophage
infiltration, elastin degradation and prevents AAA formation in the rat model of
elastase infusion induced AAA (Sweeting, Thompson et al. 2010).
In humans, men are more likely to develop AAAs. As our results from the
AngII infusion model of AAAs show a clear association of androgen with high
AAA prevalence in males via regulation of AT1aR in abdominal aortas, it is
conceivable that androgen may also influence the growth and expansion of
formed AAAs. Therefore, we hypothesized that removal of endogenous androgen
will decrease the progression of established Ang II-induced AAAs. As is shown in
Chapter II, in male ApoE-/- mice with established AAAs, castration significantly
reduced luminal dilation of abdominal aortas compared to sham control males
during an additional 8 weeks of continuous AngII infusion. A modest, but not
significant decrease in maximal external diameters of abdominal aortas was also
observed at the endpoint of the study. In contrast, it has been recently reported
that formed AAAs in nonhyperlipidemic C57BL/6 mice exhibit no further lumen
dilation when the mice are fed a high fat diet to induce obesity and then
subjected to 3 month chronic AngII infusion (Police, Putnam et al. 2010). The
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discrepancy may be explained by the different mouse models and experimental
design used in these studies.
As discussed previously, androgen exerts stimulatory effects on most
components of the RAS, including the AT1 receptor. It is conceivable that
castration reduces the progressive luminal dilation of formed AngII-induced AAAs
through inhibiting the RAS, possibly the AT1 receptor. We acknowledge that in
the current study we have not measured components of the RAS, systemically or
at local AAA tissues. Notably, a retrospective case-control study using a large
Canadian administrative database showed that patients with an AAA taking ACE
inhibitors were less likely to present with ruptured aneurysm (Hackam,
Thiruchelvam et al. 2006). In the rat elastase model of AAA, an ACE inhibitor has
been proven to significantly reduce AAA formation (Liao, Miralles et al. 2001). In
the mouse model of fibrillin 1 deficiency mimicking Marfan syndrome, losartan
has been demonstrated to effectively prevent the development of ascending
aortic aneurysm by antagonizing TGF-β, which plays a role in the progression of
tissue changes associated with Marfan syndrome (Neptune, Frischmeyer et al.
2003; Habashi, Judge et al. 2006). In the future, comparing the levels of RAS
components may provide us with insights how castration limits the luminal
expansion of established AngII-induced AAAs.
Our laboratory has previously demonstrated that weight loss in obese
C57BL/6 mice limits adventitial expansion of established Ang II-induced AAAs,
resulting in a reduction of external aneurysm diameters (Police, Putnam et al.
2010). Limited adventitial expansion in mice undergoing weight loss was
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associated with a striking decrease in neovascularization of the vessel wall
(Police, Putnam et al. 2010). Importantly, it is well known that androgen acts via
its receptor to regulate angiogenesis in the prostate and promote tumor
neovascularization growth (Colombel, Filleur et al. 2005). Indeed, androgens
have been reported to stimulate the expression of VEGF and hypoxia inducible
factor-1 (HIF-1), key mediators of angiogenesis, in the prostate (Mabjeesh,
Willard et al. 2003; Boddy, Fox et al. 2005). Therefore, one hypothesis to explain
the ability of castration to blunt AAA progression is that castration decrease
neovascularization within expanding aneurysms, limiting adventitial expansion
and resulting in a reduction in the size of established AngII-induced AAAs.
Unfortunately, this hypothesis is discordant with our findings that castration
decreased aortic lumen diameters, but not aortic wall diameters of formed AAAs.
Recent studies demonstrated that testosterone inhibits vascular calcification
(Son, Akishita et al. 2010), suggesting that castration may increase vascular
calcification and stimulate the remodeling of vessel wall. These findings suggest
that androgen may exert differential effect on luminal dilation and aortic
remodeling of established AngII-induced AAAs, via distinct mechanisms.
In conclusion, androgen stimulates AT1aR expression, particularly on
SMC, to promote AngII-induced AAA formation in adult mice. Furthermore,
castration significantly decreased the progressive lumen dilation of established
AngII-induced AAAs in male mice, suggesting that androgen plays a role in the
formation and expansion of AAAs.
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5.2.2 The role of developmental androgen in AngII-induced AAA formation
As discussed previously, during development androgen plays a vital role
in sexual differentiation of the brain and adult male behaviors as well as sexual
dimorphism of other organs. We have identified that androgen in adult mouse
mediates the prominent gender differences in AngII-induced AAAs partially by
promoting AT1aR on vascular smooth muscle cells. To investigate if
developmental androgen also contributes to a higher prevalence of AAAs in
males, we hypothesized that administration of androgen during development to
female mice will increase SMC AT1aR expression and promote Ang II-induced
AAA formation in adult females. We administered a single dose of testosterone to
female mice right after birth to mimic the effect of perinatal androgen surges
which naturally occurs in males (Weisz and Ward 1980; Corbier, Edwards et al.
1992). The neonatal administration of testosterone significantly stimulated
abdominal aortic AT1aR expression and strikingly promoted AngII-induced AAA
formation in adult female ApoE-/- and LDLR-/- mice (Chapter IV). Deficiency of
SMC AT1aR ablated the effect of neonatal testosterone on AngII-induced AAA
formation.
Notably, these effects of neonatal testosterone administration are
independent of endogenous androgen in adulthood as serum testosterone
concentrations in adult female mice were not altered by the short term exposure
to androgen during development. However, as is thoroughly reviewed by
Foecking et al, the neurosecretory control system of neonatally androgenized
females is structurally and functionally altered and therefore incapable of
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supporting cyclic GnRH and gonadotropin secretion in adulthood (Foecking,
McDevitt et al. 2008). Females that were androgenized by testosterone as
neonates exhibit a persistent estrus syndrome including anovulation, acyclic LH
secretion and attenuated pituitary responsive to GnRH (Foecking, McDevitt et al.
2008). Thus it is likely that these alterations in the endocrine system can lead to
changes in the estrogen production and secretion in androgenized female mice.
We acknowledge that estrogen measurements were not obtained in this study
due to technical difficulties. However, since previous studies for our laboratory
have demonstrated that endogenous estrogen does not regulate the formation of
AngII-induced AAA (Henriques, Huang et al. 2004), changes in estrogen levels in
androgenized females most likely did not mediate the striking increases in
susceptibility to AngII-induced AAAs of adult female mice.
Interestingly, in female mice administered testosterone as neonates
increased expression levels of abdominal aortic AT1aR were acquired following a
single exposure to testosterone and maintained through adulthood without a
continued requirement for circulating testosterone. In contrast, our results
demonstrate that male mice continue to require circulating androgen to maintain
abdominal aortic AT1aR expression in adult life. This is important as males would
be naturally under the influence of perinatal androgen surges during
development. AR mediated gene transcription often involves epigenetic
mechanisms, in which the coregulatory factors of AR modulate chromatin
structure and influence epigenetic marks. However, it has been demonstrated
that the distribution and expression level of some AR coregulators vary between
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males and females. For example, in rats many AR coregulatory factors, such as
SCR-1, CBP/p300, NCoR and SMRT, are differentially expressed in various
tissues (Misiti, Schomburg et al. 1998). Therefore, gender differences in the
expression of AR coregulators may result in variable responses to androgen
between male and female mice. In addition, recent studies have also revealed
that sex chromosomes influence the different responses to sex hormones in the
experimental model of AngII-induced hypertension (Ji, Zheng et al. 2010). It is
also feasible that the presence of an additional X chromosome, or alternatively
the absence of a Y chromosome in female mice may contribute to the different
response to neonatal androgen between male and female mice.
In addition, many investigators have discovered that the specific impacts
of developmental androgen on the adult animal vary greatly, depending on: 1) at
what “critical” period during development androgen is administered; 2) the dose
and duration of androgen exposure and 3) the animal species. For example, it is
well established that androgen (usually a single dose) is administered perinatally,
during late gestation or right after birth, to induce neuroendocrine alterations and
androgenized male-like behaviors in female rodents, sheep and non-human
primate (Pfaff and Zigmond 1971; Hrabovszky and Hutson 2002; Wallen 2005).
Recently excess androgen exposure in utero has emerged as a promising tool to
generate experimental model of polycystic ovary syndrome (PCOS) (Xita and
Tsatsoulis 2006). PCOS is a common endocrine and metabolic disorder
characterized by excess androgen production of ovarian and/or adrenal origin,
luteinizing hormone (LH) hypersecretion, hyperinsulinemia from insulin
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resistance and reduced fecundity. PCOS imposes an increased risk for type 2
diabetes and cardiovascular disease in women. It has been reported that PCOS
phenotypes can be obtained from repeated injections of pregnant rhesus
monkeys carrying female fetuses with testosterone for 15 to 35 days starting on
either days 40–60 (early gestation) or days 100–115 (late gestation) during a
total 165-day gestation (Dumesic, Abbott et al. 2007). In comparison, the
administration of testosterone during early gestation produces more traits of
PCOS, such as LH hypersecretion and increased type 2 diabetes. In this study,
we administered exogenous androgen neonatally to distinguish from the PCOS
experimental model as the metabolic syndrome phenotypes in PCOS model
would complicate the interpretation of our results. However, it is not clear
whether or not the effect of developmental androgen on abdominal aortic AT1aR
expression and AngII-induced AAA formation would sustain if exogenous
androgen was administered early in development.
Interesting, in our studies neonatal testosterone administration also
significantly enhanced AngII-induced atherosclerosis and ascending aortic
aneurysm. Previously we have demonstrated that gender differences were
restricted to AngII-induced AAAs, as male and female mice exhibited similar
levels of atherosclerosis following AngII infusion (Henriques, Zhang et al. 2008).
Recently the pathological characteristics of AngII-induced ascending aortic
aneurysms have been reported (Daugherty, Rateri et al. 2010). Preliminary
observations suggest that gender differences do not exist in AngII-induced aortic
arch aneurysms. We acknowledge that the dose of testosterone used in this
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study (400 µg/mouse) is higher than what has been used by many investigators
to androgenize females in the study of sexual dimorphism of brain (100
µg/mouse). This may contribute to the unexpected observation that two AngIIinduced vascular pathologies that do not display gender differences were
influenced by neonatal testosterone administration. In addition, SMC AT1aR
deficiency reduced the effect of neonatal testosterone to promote AngII-induced
AAAs, but had no effect on atherosclerosis or ascending aortic aneurysms in
adult female mice infused with AngII. However, theAT1aR is required for these
AngII-induced vascular pathologies. It is possible that neonatal testosterone
regulates AT1aR expression on other cells in the vasculature to promote AngIIinduced atherosclerosis and ascending aortic aneurysms. Furthermore, the
mRNA abundance of p47phox, one of the cytosolic units of NADPH oxidase, was
significantly increased in thoracic aortas of female mice administered
testosterone as neonates. It is conceivable that the increased ROS production
and oxidative stress in the vasculature of thoracic aortas may play a role in
enhanced AngII-induced atherosclerosis and ascending aortic aneurysm in this
region. Future studies should include full DNA array analysis on the aortas from
androgenized and control female mice to provide potential gene targets that may
be regulated by neonatal testosterone exposure and contribute to these AngIIinduced vascular pathologies in female mice.
In conclusion, our findings have demonstrated that a short-term exposure
to testosterone during a critical period of development increases AngII-induced
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AAA formation, via regulating SMC AT1aR, as well as other AngII-induced
vascular pathologies in adult female mice.

5.3

Future directions
Results from these studies demonstrate that androgen increases AT1aR

expression, particularly in abdominal aortic SMCs, to promote AngII-induced AAA
formation. Our studies focus on investigating the role of androgen in adult life and
during development in the formation of AngII-induced AAAs. In both studies we
have demonstrated that the enhanced AAA formation by androgen is highly
associated with the increased expression of abdominal aortic AT1aR. However,
we did not address the molecular mechanisms responsible for androgen
stimulation of AT1aR expression, especially in the abdominal aortas. Therefore,
an interesting study will be to examine the exact coregulatory factors that interact
with ARs recruited to the AT1aR promoter to increase transcription of AT1aR in
abdominal aortas.
Our results suggest that female mice exhibit long-lasting enhancement of
abdominal aortic AT1aR expression once exposed to neonatal androgen while
male mice require constant high circulating androgen to maintain higher AT1aR
expression. Our study did not address why female mice seem to be more
sensitive to the effects of neonatal testosterone administration. It is possible that
the dose of testosterone we used in the study (400 µg/mouse) causes the
circulating testosterone level in fetal females to exceed those normally found in
fetal males. Therefore, one of the future experiments could focus on defining
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effects of a lower dose testosterone, 100 µg/mouse, on AngII-induced AAA
formation as well as atherosclerosis and ascending aortic aneurysms in adult
female mice.
Another possibility is that sex chromosomes may influence the differential
responses to neonatal testosterone between male and female mice. Recently, a
powerful mouse model, name the 4 core genotypes, has been demonstrated to
enable studying the sex chromosome effects independent of the influences of
sex hormones (Arnold and Chen 2009). The 4 core genotypes includes
alternative gonadal female mice (XY–) generated by the deletion of Sry gene, the
dominant testis-determining gene, from the Y chromosome. The XY– mouse does
not develop testes but develops ovaries and expresses a female gonadal
hormone phenotype instead. Similarly, The Sry gene was also inserted onto an
autosome, creating XY–Sry and XXSry transgenic mice which are gonadal male
mice regardless of the sex chromosome complement. Therefore, by comparing
among XX and XY females and XX and XY males the effect of sex chromosome
complement can be uncoupled from the influences of sex hormone and studied
independently. One interesting study in the future should utilize the 4 core
genotype and compare XX and XY females to determine if neonatal testosterone
administration induces the same extent of AngII-induced vascular pathologies
between XX and XY females. It will allow us to dissect out the possible effect of
sex chromosomes in the different responses to neonatal androgen between the
genders.
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5.4

Clinical application

5.4.1 AAA prevention
In agreement to observations in human AAAs, our studies in experimental
AngII-induced AAAs further confirm male gender is a potent risk factor for AAA
pathogenesis. Moreover, our results suggest that male sex hormone, namely
testosterone, is a primary contributor to AAA formation and progression. In men,
androgen replacement therapy has been used to treat a variety of symptoms
associated with aging, including loss of energy, mood depression and erectile
dysfunction. Women also use exogenous androgen administration as part of
hormone replacement therapy to improve performance. Our data demonstrate
that androgen promotes AngII-induced AAA formation in both male and female
mice via upregulation of AT1aR. A significant increased risk of developing AAA
may be identified in the aging men and women who take exogenous androgen as
hormone replacement therapy as well as male and female athletes/bodybuilders
who abuse anabolic hormones. These populations with a potentially high AAA
risk should exercise precaution in using androgen as hormone replacement
therapy, look for other alternative therapy options and undergo regular ultrasound
monitoring to effective prevent AAA formation.
Although in general female gender is considered as a negative risk factor
for AAAs, the consequences tend to be more vicious once AAAs are formed in
women. For example, The UK Small Aneurysm trial reported that in patients kept
under surveillance, a 3-times higher risk of aneurysm rupture for women was
found even at a smaller diameter than men (Brown and Powell 1999). Women
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also tend to have a lower survival rate after the surgical repair of AAAs (Dueck,
Kucey et al. 2004). In addition, multiple studies have demonstrated a faster
growth rate of AAAs in women compared with men (Solberg, Singh et al. 2005;
Schouten, van Laanen et al. 2006; Mofidi, Goldie et al. 2007). Therefore, it is
important to identify the particular female population that exhibits high risk of
developing AAAs. In addition, our studies demonstrate that a short-term
androgen exposure during a critical period of development dramatically
predisposes to AAA in females when they become adults. In humans, women
suffering from PCOS experience high circulating androgen levels after puberty. It
has been reported that plasma androgen levels are higher in women with PCOS
during pregnancy (Falbo, Rocca et al. 2010). Based on 6.6% estimated
prevalence of PCOS in reproductive aged women, there are at least 4 million
women with this disease in the United States. The female offspring of these
PCOS women may become more susceptible to AAA and possibly other vascular
pathologies in adult life due to the impact of excess androgen exposure during
fetal development. It will be beneficial to raise the awareness of the potential high
risk of AAA in this particular female population.

5.4.2 AAA treatment
Currently there is no effective pharmacologic treatment to slow AAA
progression and reduce the chance of aneusymal ruptures. Recently the drugs
inhibiting the RAS, such as ACE inhibitors and AT1 receptor blockers, have been
emerged as potential treatments for this disease due to the positively protective
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effects against AAA formation observed in experimental models of AAA
(Daugherty, Manning et al. 2001; Liao, Miralles et al. 2001; Sweeting, Thompson
et al. 2010). Despite the promising findings in animal models, the effects of RAS
inhibitors on human AAA remains controversial and requires more clinical studies
to confirm the findings. For example, ACE inhibitor has been associated with
reduced AAA ruptures in a retrospective study (Hackam, Thiruchelvam et al.
2006), while in a different study the use of ACE inhibitors was recently
associated with increased growth rate of AAAs in human patients (Sweeting,
Thompson et al. 2010) . In addition, preoperative RAS inhibition before AAA
surgical repair has been reported to increase mortality in AAA patients (Railton,
Wolpin et al. 2010). However, in a recent study involving 25 years of surveillance,
treatment with an angiotensin receptor antagonist was reported to be associated
with slower AAA growth rates (Thompson, Cooper et al. 2010). Our data
demonstrate that androgen both in adult life and during development promotes
AngII-induced AAA formation through stimulating SMC AT1aR expression of the
abdominal aortas in female mice. Our findings support an important role of AT1
receptors in the pathogenesis of AAAs and indicate ARB may be beneficial as a
treatment of human AAA.

5.5

Concluding remarks
In conclusion, findings of this dissertation demonstrated that androgen,

both during development and in adult life, mediates AngII-induced AAA formation
in adult hyperlipidemic mice. These findings implicate increased expression of
161

AT1a receptor specifically in abdominal aortas as a potential mechanism
underlying androgen as a primary mediator of high AAA prevalence in m ale
gender. In addition, endogenous androgen modulates the lumen expansion of
established AngII-induced AAAs. These findings support AT1 receptor blocker as
a potential option to treat AAA and also raise the possibility of androgen
deprivation as a pharmacologic therapeutic option to limit AAA progression and
ruptures for patients diagnosed with AAA.

Copyright © Xuan Zhang 2011
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